Review

Chrononutrition—When We Eat Is of the Essence in Tackling Obesity

Maninder Kaur Ahluwalia

Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff CF5 2YB, UK; mahluwalia@cardiffmet.ac.uk

Abstract: Obesity is a chronic and relapsing public health problem with an extensive list of associated comorbidities. The worldwide prevalence of obesity has nearly tripled over the last five decades and continues to pose a serious threat to wider society and the wellbeing of future generations. The pathogenesis of obesity is complex but diet plays a key role in the onset and progression of the disease. The human diet has changed drastically across the globe, with an estimate that approximately 72% of the calories consumed today come from foods that were not part of our ancestral diets and are not compatible with our metabolism. Additionally, multiple nutrient-independent factors, e.g., cost, accessibility, behaviours, culture, education, work commitments, knowledge and societal set-up, influence our food choices and eating patterns. Much research has been focused on ‘what to eat’ or ‘how much to eat’ to reduce the obesity burden, but increasingly evidence indicates that ‘when to eat’ is fundamental to human metabolism. Aligning feeding patterns to the 24-h circadian clock that regulates a wide range of physiological and behavioural processes has multiple health-promoting effects with anti-obesity being a major part. This article explores the current understanding of the interactions between the body clocks, bioactive dietary components and the less appreciated role of meal timings in energy homeostasis and obesity.

Keywords: obesity; circadian clocks; time restricted feeding; energy homeostasis

1. Introduction

Obesity is defined as a BMI (kg/m^2) of ≥30 (further classified into class I (BMI 30.0 to 34.9), class II (BMI 35 to 39.9) and class III (BMI > 40.0) and a BMI between 25.0–29.9 is classified as overweight [1,2]. The World Health Organisation defines obesity as a disease and not just the biggest risk factor for the development of multiple non-communicable chronic diseases, such as metabolic syndrome, diabetes, hypertension, cardiovascular diseases and cancer [3]. The cost to treat obesity and associated diseases puts an immense pressure not only on the healthcare sector but also wider society. The rate of obesity is rising globally inexorably and most projections indicate that without a concerted action, by 2035 over 45% of the global population will be either overweight or obese [4].

The pathogenesis of obesity is complex, with multifaceted interactions between an individuals’ genetics and the environment. Although evidence suggests that there is 40–70% heritability for obesity, environmental factors, particularly diet and physical activity, are critical to its onset and progression [5]. At its simplest, obesity is a result of positive energy balance and the relatively lower cost and abundance of energy-dense foods occurring concomitantly with an increasingly sedentary lifestyle have driven the obesity pandemic. In many modern societies, a 24/7 work and social lifestyle has become the norm, leading to erratic sleep and food-consumption patterns, disrupting the harmony between the biological day/active phase and metabolic processes and further fuelling the crisis [6,7].

There is no simple solution to address the escalating obesity epidemic. Lifestyle interventions have been the focus of weight-loss strategies with limited success and issues with long-term compliance. Body clocks, present in virtually each cell in the body, synchronise
all physiological and biochemical processes to the external environment of light/dark cycles, temperature and food availability. The internal body clocks also coordinate the metabolic processes in a way that light/dark cycles are aligned with active/rest and anabolic/catabolic reaction phases and the loss of this harmony leads to adverse metabolic outcomes. The relatively novel concept of chrononutrition, the interactions between the food components and timing with circadian mechanisms, offers a promising target for designing sustainable weight-management strategies.

2. Chronobiology

Life evolved and adapted to the light/dark cycles that are a result of the earth’s rotation on its own axis. Organisms have an internal 24-hour circadian (from the Latin words circa diem, about a day) clock that adapts their daily activities to their external environment. Zeitgebers (external cues that synchronise the biological rhythms) such as light/dark cycles entrain (synchronise) the circadian system to generate rhythms in bodily processes, including the sleep/wake cycle, immune activity, metabolism, body temperature and blood pressure.

At the molecular level, the circadian clock in mammals is composed of two sub-systems: the core and the peripheral clocks. The core circadian clock is situated in the anterior hypothalamus and includes the suprachiasmatic nucleus (SCN), composed of about 20,000 neurons, for which light is the primary zeitgeber. Light enters the eye and the photic signal is conveyed to the SCN, where it is integrated with non-photic signals that include food and external temperature [8]. An endogenous rhythm is generated and communicated to other parts of the brain and to peripheral organs via direct neuronal synaptic connections and endocrine signals, aligning the whole-body circadian clock to light. In addition to the core pacemaker, each cell in the body has its own local clock with its autonomous daily rhythmicity. These peripheral clock systems are influenced by the SCN but are also entrained by SCN-independent zeitgebers such as meal timing, locomotor activity and body temperature [9,10]. During the night, the SCN also regulates the synthesis and release of melatonin by the pineal gland. Melatonin is a sleep-inducing hormone with 24-hr rhythmicity; its production is inhibited by light, hence its low circulatory levels during the day [11]. The levels of melatonin start to rise approximately 2–3 h prior to the habitual nocturnal sleep time that also coincides with the onset of dim light conditions in the evening. This is defined as dim-light melatonin onset (DLMO), and is a reliable marker for the circadian entrainment [12,13]. Melatonin exerts its biological effects by binding to melatonin receptors, human melatonin receptor 1 A and 1 B (MTNR1A and MTNR1B). Sleep is an important modulator for multiple metabolic and endocrine pathways, linking melatonin levels, sleep duration and quality with obesity [14,15]. Melatonin also inhibits glucose-mediated insulin secretion and effects free radical scavenging, thus contributing directly to regulation of metabolic and immune function [16].

Genomics and Epigenomics of Chronobiology

An intricate programme of transcription-translation-posttranslational feedback loops controls the complex patterns of circadian rhythmicity in physiology and behaviour (Figure 1). During the day, the key players responsible for the oscillations of circadian rhythms include the circadian locomotor output cycles kaput (CLOCK) and brain and muscle Arnt-like protein-1 (BMAL1). These heterodimerise and CLOCK-BMAL1 binds to the E-box regulatory element in the promoter regions of multiple circadian genes. Primarily, these activate the expression of PER (Period PER1, PER2 and PER3) and CRY (Cryptochrome CRY1 and CRY2) genes. Upon translation and a time lag (by the end of the day), these PER and CRY proteins accumulate in the cytoplasm and once they reach certain level, these heterodimerize to form a repressor complex and translocate to nucleus where they inhibit CLOCK-BMAL1-mediated transcription. Towards the end of the night, there is a gradual degradation of PER and CRY proteins that leads to the release of the CLOCK-BMAL1 dimer from PER/CRY suppression, and this re-initiates the clock cycle by
inducing the transcription of PER and CRY. This cycle of activation and repression results in a feedback loop that generates an oscillation pattern of PER and CRY proteins over a 24-h period [9,17,18].

Figure 1. Circadian clock mechanisms: different zeitgebers lead to intricate transcription-translation feedback loop. circadian locomotor output cycles kaput (CLOCK) and brain and muscle Arnt-like protein-1 (BMAL1) heterodimerise and regulate the transcription of multiple clock-dependent genes (solid arrows). PER, CRY, REV-ERBα, RORα, PPARα, PPARγ, SIRT1 all lead to regulation of CLOCK and BMAL1 and contribute to their own regulation (dotted arrows). Amplitude, period, phase and MESOR of the oscillations produced determine the rhythmicity and robustness of the circadian clock. PER (Period), CRY (Cryptochrome), RORα (receptor-related orphan receptor α), REV-ERBα (NR1D1 gene producing a protein called REV-ERBA), PPARα (peroxisome proliferator-activated receptor α), PPARγ (peroxisome proliferator-activated receptor γ), NAMPT (nicotinamide phosphoribosyltransferase), NAD+ (nicotinamide adenine dinucleotide), AMPK (AMP-activated protein kinase), CCGs (clock-controlled genes), SIRT1 (sirtuin 1), PGC1α (PPARγ coactivator 1α), MESOR (midline estimating statistic of rhythm).

A parallel secondary loop exists that improves the robustness of the primary loop, consisting of the transcriptional factors nuclear receptor subfamily 1, group D, member 1 (NR1D1 gene producing a protein called REV-ERBα) and retinoic-acid-receptor-related orphan receptor α (RORα). The transcription of these genes is also activated by CLOCK-BMAL1 through binding to the E-box element in their promoters. REV-ERBα and RORα then compete to bind to the ROR element (RORE) in the BMAL1 promoter and regulate BMAL1 transcription; REV-ERBα suppresses while RORα stimulates BMAL1 transcription. Two other members of the nuclear receptor family, peroxisome proliferator-activated receptor α (PPARα), and PPARγ coactivator 1α (PGC1α) are activated by CLOCK-BMAL1. Interestingly, PPARα and PGC1α also activate BMAL1 transcription (Figure 1) [19–22].

The clock components are also under the control of various post-translational modifications including phosphorylation, ubiquitination, acetylation, poly-ADP-ribosylation and proteasomal degradation. This additional layer of regulation allows plasticity in the circadian system, making them highly responsive to an organism's environment [23]. PER, CRY and PGC1α are all modified in response to the nutritional status of the cell, have an impact on the inhibitory period on CLOCK-BMAL1 and contribute to the changes in rhythmic patterns. CLOCK is an acetyltransferase and acetylates its partner BMAL1 and regulates the transcriptional activity of the heterodimer. CLOCK itself can be modified by poly-ADP-ribosylation leading to the transcriptional inhibition of CLOCK-BMAL1 target genes and altering the circadian cycle [24–26].
Circadian regulation is not limited to the core clock-network genes mentioned above; approximately 10–40% of the rodent genes in a tissue and >80% of the protein coding genes in baboons have been found to exhibit 24-hr rhythmic oscillations, resulting in identification of these genes as clock-controlled genes, “CCGs” [27]. These CCGs regulate various biological processes including apoptosis, metabolism, detoxification, cell-cycle regulation and immune function [28–30]. Some genes are under the control of SCN-generated rhythms, but a large proportion of genes are influenced by tissue-specific peripheral clocks. It has been shown that in mouse liver, 90% of the transcripts showing circadian oscillations are under the influence of local clock machinery [31].

The oscillations produced are characterised by their amplitude (magnitude of cycle reflecting the strength of the rhythm), period (the time interval between two recurring waves within a rhythm), phase (any time point on a rhythmic cycle, e.g., peak relative to an external reference such as midnight) and MESOR (midline estimating statistic of rhythm). These features indicate the rhythmicity and robustness of the circadian clock and any changes in these parameters can be a predictor of health-related outcomes (Figure 1) [32–34]. Secondly, the rhythms generated by the core and peripheral clock systems need to be aligned given that misalignment between the clocks can potentially disrupt the body’s physiological patterns and metabolism.

3. Chronotypes, Chronodisruption and Energy Homeostasis

The circadian cycle for humans has an average period of 24.2 h, but this period varies considerably between individuals and is defined as their chronotype [35]. Chronotypes range between early birds (morning people/advanced sleep phase (ASP)/early chronotypes, people going to bed and waking up early, circadian period shorter than 24.2 h) to night owls (evening people/delayed sleep phase (DSP)/late chronotypes, people preferring late bedtime and waking up late, a circadian period longer than 24.2 h). It is estimated that about 40% of the population can be classified into either of these extremes [35,36]. There is a continuum between these two extreme phenotypes, and individuals within this category are referred to as belonging to the intermediate or neutral chronotype; about 60% of the population falls into this category [37]. Melatonin rhythms and DLMO vary by as much as 2 h between the chronotypes [38]. Certain rare and genetic forms of extreme chronotypes have also been recognised. A type of insomnia where sleep patterns are shifted to a delayed onset and offset times compared to the societal norm is known as delayed sleep phase disorder (DSPD), while a phenotype associated with habitual sleep times that are earlier than the solar morning or societal norm is termed familial advanced sleep phase disorder (FASPD) [39]. In addition to the age, gender and societal set-up, an individual’s chronotype is also influenced by their genetic makeup and various genome-wide association studies (GWAS) and candidate-gene approaches have associated more than 350 loci with the morning chronotype and, not surprisingly, these include the components from the clock machinery [40]. Genetic variants within the clock machinery have been associated with sleep patterns, variation in energy intake, waist circumference, obesity and metabolic diseases (Table 1) [41–43]. Both morning and evening chronotypes are multigenic and are influenced by the environment, whereas non-genetic factors such as artificial light and social pressures contribute more to the evening chronotype [44]. Although these chronotypes result in a preferred choice of sleep and activity patterns, these do not directly contribute to the pathogenesis of metabolic diseases. However, some recent studies have suggested a link with these morningness or eveningness tendencies and metabolic health. The evening chronotype has been associated with unhealthy food choices, binge eating, night snacks and multiple metabolic disorders, including obesity, while morning individuals are associated with lower rates of depression and improved mental health [40,44–50]. The chronotype of an individual determines their sleep, dietary and activity patterns and although they indirectly influence the sleep duration and quality, these are distinct from sleep duration [51]. Any forced disruption to the normal sleep patterns, e.g., shift work or frequent traveling over two or more time zones (jetlag), can lead to circadian misalignment and have been
associated with various metabolic diseases. An individual with the evening chronotype tends to go to bed late but due to external demands (occupational commitments such as working hours or school start time in case of children) would result in waking up to an alarm clock that is out of phase from their biological circadian cycle, resulting in shorter sleep duration. There can also be variation in bedtime within the week, e.g., weekdays vs. the weekends, leading to the concept of social jet-lag. These societal activities indirectly contribute to metabolic health (Table 1) [16,44].

Table 1. A summary of genetic variants in clock components and their associations with chronotypes, eating behaviours and health parameters.

| Genetic Variant/Haplotypes         | Population                                      | Observations                                                                 | Ref |
|-----------------------------------|-------------------------------------------------|-------------------------------------------------------------------------------|-----|
| CLOCK rs1801260                   | 421 Japanese subjects                           | C allele associated with an evening chronotype with significant delayed onset of sleep, shorter sleep times, greater daytime sleepiness | [52]|
|                                  | 500 overweight and obese subjects during 28-week weight-loss program | C allele carriers more emotional eaters and more resistant to weight loss     | [53]|
|                                  | 284, 92 controls vs. 192 overweight and obese with or without binge eating disorder | C allele predisposes obese individuals to a higher BMI                        | [54]|
|                                  | 1272 overweight and obese participants attending 30-week weight-loss program | C allele carriers were emotional eaters and lost less weight and at a lower rate compared to non-emotional eaters with the same risk allele or non-risk allele | [55]|
|                                  | 370 children aged 6–13 years                    | No association between the genotype and sleep duration. However, there seems to be a trend between sleep duration and overweight | [56]|
|                                  | 85 overweight women                              | C allele carriers with significant circadian abnormalities: lower amplitude and greater fragmentation of the rhythm, and an evening chronotype | [57]|
|                                  | 1495 overweight/obese subjects participating in a Mediterranean-diet-based weight-reduction program for 28 weeks | C allele carriers are more resistant to weight loss, shorter sleep duration, higher plasma ghrelin concentrations, delayed breakfast time, evening preference and less compliance with a Mediterranean diet plan | [58]|
|                                  | 475 metabolic syndrome subjects participating in the CORDIOPREV clinical trial for 1 year | Gene diet interactions; C carriers showed non-significant improved insulin sensitivity while T carriers have significantly improved insulin sensitivity on low-fat diet | [59]|
| CLOCK haplotype rs1554483 and rs4864548 | 715 lean and 391 overweight or obese | GA haplotype associated with a 1.8-fold risk of overweight or obesity | [60]|
| CLOCK rs3749474                  | 500 overweight/obese subjects                   | T allele carriers have significantly higher weight, BMI and waist circumference | [53]|
| CLOCK rs3749474                  | 1100 individual participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) | T allele carriers have significantly higher energy, total fat, protein and carbohydrate intakes | [61]|
| CLOCK rs3749474                  | 898 subjects                                    | T allele associated positively with higher BMI and evening carbohydrate intake | [62]|
| CLOCK rs6850524                  | 260 cases with abdominal obesity and 260 controls Chinese population | CC genotype have a lower risk of overweight or obesity than those with GG genotype | [63]|
| CLOCK haplotype rs4864548-rs3736544-rs1801260 | 537 individuals from 89 families characterized for inflammatory, atherothrombotic and metabolic risk associated with insulin resistance. | CGC haplotype protective for the development of obesity and the CAT haplotype is associated with the presence of the metabolic syndrome | [64]|


Table 1. Cont.

| Genetic Variant/Haplotypes | Population | Observations | Ref |
|----------------------------|------------|--------------|-----|
| CLOCK rs4580704            | 7098 PREvención con Dieta Mediterránea (PREMED) trial over a median duration of 4.8 years | G allele with decreased incidence of type 2 diabetes and associated stroke. Mediterranean diet provides further protection in G allele carriers. | [65] |
|                            | 897 patients from the CORDIOPREV clinical trial, low-fat diet and Mediterranean diet for 12 months | C allele carriers showed significant reduction in CRP levels and an improvement in HDL/ApoA1 ratio after a low-fat diet for 12 months | [66] |
|                            | 1100 individual participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) | G allele show lower blood pressure and higher erythrocyte membrane oleic acid (MUFA) and improved insulin sensitivity in high-MUFA intake | [67] |
|                            | 1100 individual participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) | The haplotype CGA was associated with lower BMI, weight, waist circumference, adiponectin concentration, blood pressure and with oleic acid (MUFA) RBC membrane composition. | [67] |
| CLOCK rs12649507, rs6858749 | 14,906 from the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium | Longer habitual sleep duration is associated with lower BMI and a favourable dietary behaviour. rs12649507 G allele: Higher PUFA intake and more sleep.rs6858749 T allele: Lower protein intake with each additional hour of sleep | [68] |
|                            | 260 cases with abdominal obesity and 260 controls, Chinese population | Significant associations between CG and TG haplotypes and abdominal obesity. rs10002541 C allele is protective for abdominal obesity. | [63] |
| CLOCK rs12649507 and rs11932595 | 1011 individuals from Tyrol and Estonia | The haplotype GGGG in Tyrolean and GGA in Estonian population associated with longer sleep | [69] |
|                            | 507 healthy young adults | CLOCK rs1801260 associated with seasonal affective disorder and it synergistically interacts with BMAL1 rs2278749. Seasonal variation in body weight and appetite also associated with BMAL1 rs2278749. | [70] |
| CLOCK rs1801260 + SIRT1 rs1467568 | 1465 Overweight/obese subjects over 30 weeks of Mediterranean-diet-based weight-loss program | SIRT1 (A allele) ad CLOCK (C allele) are more resistant to lose weight and have more of an evening preference | [71] |
|                            | 454 obese subjects, weight reduction program based on Mediterranean diet | PER2 gene rs4663302 rs2304672 associated with abdominal obesity. rs4663302 T allele and rs2304672 G allele carriers associated with not completing the weight-loss programme. rs2304672 G also linked to extreme snacking, experiencing stress with dieting, eating when bored, and skipping breakfast than noncarriers. | [72] |
| PER2, BMAL1, and NPAS2      | 189 patients with winter depression and 189 matched controls | PER2 rs10870, BMAL1 rs2290035 and NPAS2 rs11541353 significantly association with SAD | [73] |
|                            | 260 cases with abdominal obesity and 260 controls, Chinese population | CRY1 rs10861688 T allele negatively associated with the risk of abdominal obesity. | [63] |
|                            | 2212 subjects from two independent populations (1402 from Spanish Mediterranean and 810 North American) | Minor allele carriers (AA + AG) have lower probability of abdominal obesity than noncarriers. A allele carriers on low MUFA lead to high BMI while A carriers on high MUFA reduce BMI and BMI was low in A carriers in high-PUFA intake | [74] |

There is an intricate and bidirectional relationship between the circadian clock and metabolism that contributes to the overall metabolic homeostasis. There needs to be an optimal alignment between central and peripheral clock requiring energy intake to be aligned with the active phase/biological day for diurnal organisms such as humans (and night-time for nocturnal animals such as rodents). Mice consume about 80% and humans
approximately 100% of the nutrients during the wake/active phase [75]. This pattern is in-tune with the oscillations in metabolic pathways of primitive hunter-gatherer humans, who were exposed to feast/famine cycles that coincided with active/rest phases. During the active phase, when humans could forage and hunt for food, the energy intake was higher and the metabolic pathways were geared towards replenishing the energy stores. While famine, generally associated with rest meant that the body had to adapt to starvation or restriction in food intake and the metabolism would switch to catabolic processes and mobilisation of energy stores. Humans are genetically programmed to these oscillations in energy stores, which is incompatible with a modern lifestyle with the constant availability of high-energy foods.

These results, when combined with a sedentary lifestyle, blunt the oscillations and lead to metabolic disturbances with a plethora of associated diseases [76–78].

Misalignment in the active/rest and feast/famine phases can be due to endogenous factors, e.g., genetic variants in the core clock machinery or due to external lifestyle factors such as extended exposure to artificial light, increased shift work, sedentarism, untimely and frequent snacking and jetlag, and leads to chronobiological vulnerabilities to various diseases (Table 2) [46,79–82]. An umbrella term used for circadian disruptions is ‘chronodisruption’. The term has evolved since it was first coined in 2003, with short-term disturbance being called circadian disruption. In contrast, long-term disturbances leading to adaptations without a negative impact on health are termed chronodisturbance, and long-term desynchronisation contributing to disease is called chronodisruption [83]. Artificial light exposure, even at low levels such as from electronic devices including phones, also interferes with the DLMO and melatonin levels, sleep onset and duration [16,44,84]. Additionally, night eating, irregular eating patterns or feeding over the resting periods even in the absence of evening chronotype lead to misalignment and impact the robustness of the oscillations, compromising the metabolic homeostasis and leading to higher BMI and disease development (Figure 2) [76,85–95].

![Figure 2](image_url)

**Figure 2.** Master (blue) and peripheral clocks (pink) alignment is key to optimal metabolic health. Chronodisruption by various means leads to misalignment of circadian rhythms and has health consequences. Chrononutritional approaches have the ability to reverse deleterious chronodisruptive rhythms. The dotted line represents MESOR (midline estimating statistic of rhythm).

**Table 2.** A summary of evidence establishing the role of chronodisruption by mistimed eating habits and associated BMI and metabolic health outcomes.

| Late Night Eating, BMI and Metabolic Health | [87] |
|-------------------------------------------|------|
| 180 bariatric surgery candidates, 93 non-surgical weight-loss intervention and 158 general community candidates | Night-eating syndrome associated with binge eating, higher BMI and male gender. Night-eating syndrome, consuming nocturnal snacks leads to more hunger and depressive symptoms. |
### Table 2. Cont.

| Late Night Eating, BMI and Metabolic Health |
|--------------------------------------------|
| **26,902 men over 16 years follow-up** | Late night eaters have a 55% higher risk of CHD, are more likely to have baseline hypertension and men who did not eat breakfast have a 27% higher risk of CHD than those who ate breakfast. [90] |
| **8153 adults over an average of 3.9 yrs.** | Night-time eating associated with dyslipidaemia in both men and women but metabolic syndrome and an increase in the risk of obesity only in women [96] |
| **10 participants on glucose solution at 8 am and 8 pm and 9 participants taking a low-glycaemic-index meal at 8 am, 8 pm and midnight.** | Even low-glycaemic-index meals late at night disturb glucose metabolism [86] |
| **19,687 Japanese women** | Skipping breakfast, late dinner and bedtime snack associated with overweight and obesity in Japanese women [97] |
| **397, 8–12 yr old children** | Late dinner eaters (after 21.07 h) were more likely to be overweight and obese, with higher waist circumference and inflammatory markers [98] |
| **49 participants** | Inconsistent meal time, especially late, eaters have significantly higher BMI [99] |
| **100 subjects** | Correlation between night-time eating and binge eating and BMI [88] |

### Later chronotype, BMI and metabolic health

| **2200 9–16 yr old in Australia** | The later chronotype more likely to be overweight and obese [100] |
| **54 college freshmen** | An evening chronotype associated with higher BMI as compared to morning or neutral chronotypes [49] |
| **511 UK 11–13 yr old children** | An evening chronotype was associated with higher BMI, higher frequency of unhealthy food choices. Sleep duration is an independent risk factor for BMI [101] |
| **194 participants** | Later chronotype and larger dinner are associated with poorer glycaemic control in patients with type 2 diabetes independently of sleep disturbances. [45] |
| **439,933 adults from a UK biobank** | Evening preference associated with high risk of cardiovascular disease [46] |
| **800 undergraduate students** | Evening chronotype associated with BMI that can be negated by a decrease in sugary beverage intake, increases in physical activity [47] |
| **2133 prediabetic patients** | More evening preference is directly associated with higher BMI [48] |
| **872 adults** | Later chronotypes with higher percentage of daily energy intake during the night are associated with overweight and obesity while earlier chronotypes consuming more energy in the morning are at a lower risk of weight gain. [102] |
| **1197 middle-aged men and women** | An evening chronotype associated with obesity [50] |

### Circadian misalignment, BMI and metabolic health

| **14 healthy participants on 8-day protocol for short-term misalignment and cross over** | Short-term circadian misalignment leads to increased systolic and diastolic blood pressure and serum inflammatory markers [103] |
| **14 adults in a 6-day simulated shift-work environment** | Eating during the biological night, e.g., for shift workers, decreases total daily energy expenditure and increases the risk of weight gain and obesity [89] |
| **10 adults underwent a 10-day protocol with eating and sleeping in all phases** | Forced desynchrony protocols cause circadian misalignment and disturb postprandial glucose response typical of prediabetes [104] |
| **2494 participants (1259 day and 1235 shift workers)** | Shift work is associated with higher risk of being overweight/obese [105] |

### Long-term shift work is associated with metabolic syndrome [106]

| **26,382 participants (9088 shift workers)** | Long-term shift work is associated with metabolic syndrome [106] |
| **9912 male employees (8892 daytime workers and 920 rotating three-shift workers** | High risk of obesity among male shift workers [107] |
| **905 shift workers** | Strong association between sleep deprivation and obesity in shift workers [108] |
| **200 shift workers** | Night work is a risk factor for abdominal obesity, social jetlag is higher in night shift workers and it was associated with the presence of obesity. [109] |
| **3188 shift workers and 6395 non-shift workers** | Shift work associated with obesity, lower physical activity, poor dietary choices [110] |

### 4. Chrononutrition

Understanding the molecular basis of chronodisruption can potentially allow us to develop practical strategies to improve circadian alignment to mitigate the burden of metabolic diseases. One such relatively novel approach is termed ‘chrononutrition’, en-
compassing two elements: dietary components that regulate circadian system and meal timings to synchronise misaligned molecular clocks, which can act either positively or negatively on metabolic activity. These interventions (including physical activity) can improve the blunted rhythmic oscillations; even if these are not as robust as those accompanying feast/famine cycles, they can potentially be associated with positive metabolic health outcomes (Figure 2) [111].

4.1. What to Eat

It is well-established that nutritional components, including macronutrients and natural bioactive compounds, have the ability to (directly or indirectly) regulate the expression of various genes, and clock-network genes are no exception [112–115]. While feeding/fasting patterns mainly act as a potent zeitgeber for peripheral clocks and minimally impact the master clock, nutritional components are also able to influence the master clock in the SCN [116–118]. High-fat diets are the best-known circadian rhythm disruptors and can lead to the reversal of feeding patterns and perturbed metabolic parameters [117,119–122]. The relative distribution of macronutrients in diet can also contribute to central and peripheral clock modulation in humans [115,123]. Other nutrients have been investigated for their role in circadian remodelling; a ketogenic diet increases the activation of CCGs via CLOCK-BMAL1 activation, high sodium and high salt intake causes a phase delay in BMAL1 and CRY1 and PER2 peak expression and caffeine and theophylline lengthen the period of the cellular circadian clock [124–127].

A growing body of evidence is emerging that links the use of natural bioactive compounds to health via synchronising or improving circadian rhythmic patterns and potentially acting as a natural chronobiotic—an agent with the ability to adjust the timing of one’s internal biological rhythm. The best studied chronobiotic is melatonin, which when administered exogenously can shift the circadian clock phase and alter circadian rhythms in endogenous hormones, body temperature and behaviour [128]. There is also evidence that melatonin supplementation not only modulates body weight and metabolic parameters but also has the ability to reverse the metabolic perturbations caused by chronodisruption [129,130]. Most of the melatonin supplementation has been in a synthetic form through capsules, but melatonin also exists in natural food sources such as fish, eggs, poultry, milk, nuts, fruits and seeds [131]. Natural plant derivatives such as phytochemicals, plant bioactives and nutraceuticals have gained significant attention for their health-promoting properties. Plant polyphenols are one of the most abundant and widely distributed group of secondary metabolites driven from plants. A diverse range of polyphenolic compounds, including phenolic acids, flavanones, flavonoids, tannins, lignans, stilbenes and curcuminoids, have been associated with anti-obesity activities via a variety of mechanisms [132–135]. Although the exact mechanisms of their actions remain unclear and there are issues around their absorption, bioavailability and bio-accessibility, evidence suggests that some of the beneficial effects of these compounds are mediated by their ability to interact with circadian clocks via genetic/epigenetic mechanisms or indirectly via altering the gut microbiota (Table 3) [136,137]. These interactions are complex; phytochemical content from the plant source depends on various agricultural factors such as soil, light, season, temperature and even the endogenous circadian clock of the plant [138]. There are also seasonal factors, e.g., availability, polyphenolic composition from the same source and human-consumption patterns, which can add another layer of complexity to the seasonal biological oscillations over the period of 12 months, called circannual rhythms [138–140]. The timing of consumption of these compounds is also critical, as demonstrated by a study using tryptophan-enriched milk formula in infants. Infants taking tryptophan-enriched formula during the night had improved sleep parameters as compared to those who consumed it during the day [141]. Table 3 presents some of the direct interactions observed between the polyphenolic compounds, circadian mechanisms and health outcomes.
Table 3. A summary of polyphenols with their interactions with circadian system and role in health.

| Polyphenol         | Interactions with Circadian Clocks                                                                 | Reference          |
|--------------------|----------------------------------------------------------------------------------------------------|--------------------|
| **Resveratrol**    | Improvement in rhythmic expression of core clock and various clock-controlled genes including NAMPT, SIRT1, PPARα | [142–148]          |
|                    | Improvement of insulin, glucose, lipid metabolism impairments caused by chronodisruption            |                    |
|                    | Prevention of neuron damage and memory impairment caused by circadian disruption                    |                    |
|                    | Enhanced expression of PER1, PER2 and BMAL1 in rat fibroblasts                                      |                    |
|                    | Downregulation of high-fat diet induced REV-ERBα in adipose tissue                                 |                    |
|                    | Reversal of free-fatty-acid-induced loss of oscillation amplitude in core clock genes in HEPG2 cells|                    |
|                    | Amelioration of acrylamide suppressed amplitude and phase of oscillations in core clock genes and increased expression of SIRT1 and PGC1α |                    |
|                    | Increase in expression of BMAL1, PER1, SIRT6, SIRT1 and REV-ERBα mRNA in fibroblasts                 |                    |
| **Proanthocyanidins** | Modulation BMAL acetylation, increase in PER2 expression and inhibition of REV-ERBα and RORα in rat models of diet-induced obesity | [149]              |
|                    | Modulation of NAMPT expression and NAD⁺ levels in rat liver                                        |                    |
| **Epigallocatechin-3-gallate** | Altered circadian expression patterns of CLOCK, BMAL1 and key appetite-regulating genes in mice | [150–152]          |
|                    | Ameliorated diet-induced metabolic misalignment by regulating the rhythmic expression of the circadian clock genes in the liver and adipose tissue in mice |                    |
|                    | Repressed CLOCK expression in lung cancer cell lines and reduced the self-renewal capacity of the cells |                    |
| **Nobiletin**      | Affects amplitude, period and phase of mutant mice cells with weaker rhythmic amplitude.             |                    |
|                    | Activation of RORs and protection against metabolic syndrome in a clock-dependent manner.            |                    |
|                    | Enhances BMAL1, reverses the loss of oscillation amplitude observed in metabolic disease state       |                    |
|                    | Induction of AMPK-SIRT1 signalling and lipogenesis                                                   |                    |
|                    | Ability to induce circadian rhythmicity and inhibit oncogenicity in MDA-MB-231 cells               |                    |
|                    | Modulates expression of core clock and clock-controlled genes in the cortex                          | [153–162]          |
|                    | Restores endogenous rhythm of clock genes in steatosis liver                                        |                    |
|                    | Modulates clock and Alzheimer’s-disease-related genes in cortex of AD model mice                    |                    |
|                    | Cardioprotective role in ischemia reperfusion injury by upregulating midazolam-inhibited PER2       |                    |
|                    | Improves metabolic fitness in naturally aged mice and promotes healthy aging in high-fat diet by activating genes to promote mitochondrial function |                    |
|                    | Improves insulin secretion by enhancing the amplitude of circadian gene expression in T2D islets    |                    |
### Table 3. Cont.

| Polyphenol | Interactions with Circadian Clocks | Reference |
|------------|-----------------------------------|-----------|
| Oolong tea polyphenols | Improves *Firmicutes:Bacteroidetes* ratio in the intestinal flora in mice | [163,164] |
| | Promotes the growth of strains of gut microbiota and positively regulates the production of SCFA | |
| | Restoration of CLOCK, BMAL1, PER and CRY expression disturbed by constant day feeding in mice | |
| Chichoric acid | Regulation of rhythmic expression of clock genes | [165] |
| Quercetin | Upregulation of BMAL1, SIRT1, SIRT6, REV-ERBα and reduction in PER1 expression in fibroblasts | [148,166] |
| | Suppresses breast cancer metastasis to lymph nodes promoted by circadian disruption | |

CLOCK (circadian locomotor output cycles kaput), BMAL1 (brain and muscle Arnt-like protein-1), PER (Period), CRY (Cryptochrome), RORs (receptor-related orphan receptor s), REV-ERBα (NR1D1 gene, producing a protein called REV-ERBα), NAMPT (nicotinamide phosphoribosyltransferase), SCFA (short chain fatty acids), T2D (type 2 diabetes), SIRT6 (Sirtuin 6), SIRT1 (sirtuin 1), AMPK (AMP-activated protein kinase).

### 4.2. When to Eat

Interestingly, other than what goes on your plate, chrononutrition also highlights the significance of aligning the meal timing, frequency and the patterns of energy intake with the circadian rhythm [167]. The concept of ‘when you eat’ was first proposed in 1967 as a link between the meal timing, energy metabolism and chronic diseases by Franz Halberg [168,169]. Food consumption is a strong entrainer for peripheral circadian clocks. Optimal health requires an alignment of energy intake with the biological day and active phase and to generate feed/fast cycle that human physiology is adapted to. The transition between the feed/fast cycles requires a different set of transcription factors and associated proteins, which display diurnal variation. Genes that are active and peak during the day are mainly associated with glycogenesis and lipogenesis, with an overall aim of replenishing the energy stores, while the fasting phase is enriched with genes responsible for growth, repair, glycogenolysis and lipolysis. Any perturbations in the availability of the key players in either of these phases and dietary intake could lead to the dysregulation of energy metabolism [21,170,171]. The same meal consumed at different times during the circadian cycle could have a varied impact on energy metabolism. The current 24/7 lifestyle and a constant supply of nutrients interrupts human circadian physiology. Emerging data suggest that the eating window for more than 50% of the population (non-shift-work) is approximately 15 h a day, with less than 30% of energy consumption happening before noon and 30–45% of daily energy consumed during dinner and post-dinner snacks and part of it spanning over the circadian rest period [172–174]. The increased eating window and shorter overnight fast contributes to increased energy intake. Mistimed eating accompanied by erratic sleep patterns leads to dampened circadian rhythms and increases the risk of metabolic disorders (Table 2). Interestingly, the dampening of circadian rhythms by a high-fat diet can be recovered from by just limiting food intake during the biological active phase, highlighting the importance of “when to eat” and aligning meals with our biological clocks [175].

Time-restricted feeding (TRF) in animals (time-restricted eating (TRE) in humans) is an approach that aims to align meal times with the circadian rhythm and has gained significant attention in recent years. Multiple animal and human studies have been conducted and some human feasibility studies and clinical trials are summarised in Table 4.
Table 4. A summary of human studies investigating the impact of time-restricted eating in humans and metabolic health outcomes.

| Participants | Eating Restrictions | Study Type/Duration | Health Outcomes | Energy Intake | Reference |
|--------------|---------------------|---------------------|-----------------|--------------|-----------|
| n = 49 obese subjects BMI 30–50 kg/m² | Eating window of 4 h (3 pm–7 pm) vs. 6 h (1 pm–7 pm) vs. controls (7 am–7 pm) | Randomized parallel-arm trial over 8 weeks | Both TRF regimens showed reduction in body weight, insulin resistance, oxidative stress levels. Four-hour TRE did not result in greater weight loss compared to six-hour TRE. | Reduction in energy intake by 550 kcal/day in both cases without calorie counting | [176] |
| n = 11 Obese sedentary males BMI: 30.2–34.2 kg/m² | Eating window 10 am–5 pm vs. 7 am–9 pm | Randomized crossover trial; 3 weeks each intervention of 5 days with 10 days washout period | Improved glycaemic control and decrease in evening hunger | Isocaloric intake | [177] |
| n = 19 with T2D BMI: 29–39 kg/m² | 4-week TRE 10 am–7 pm | non-randomised 2-week baseline, 4-week intervention | Compliance 72 ± 24%, no improvement in glycaemic control or body mass | Isocaloric intake | [178] |
| n = 23 obese subjects BMI 30 and 45 kg/m² | Eating over 8-h window (10 am–6 pm) vs. ad libitum eating | 2-week baseline intake, 12-week intervention | Time-restricted eating showed reduction in body weight and systolic blood pressure | Decreases caloric intake by ~300 kcal/d | [179] |
| n = 34 resistance-trained weight 84.6 ± 6.2 kg | TRF (1 pm–8 pm) vs. control (8 am–8 pm) | Randomized parallel-arm trial over 8 weeks | TRF only showed a reduction in fat mass but no other metabolic parameters were altered. Fat free mass and muscle mass area in arm and thigh remain unchanged | Isocaloric intake | [180] |
| n = 9 overweight sedentary older adults BMI 25–40 kg/m² | 16 h fast (14–18 h range) | Baseline assessment followed by 4-week intervention | TRE resulted in short-term weight loss and improved waist circumference, cognitive and physical function and health-related quality of life | No data available | [181] |
| n = 8, prediabetic BMI 32.2 ± 4.4 kg/m² | eTRF; 6-h eating period and dinner before 3 pm for 5 weeks, vs. 12-h eating period | Randomized crossover trial for 17 weeks, each intervention 5 weeks | eTRF reduced insulin levels and improved insulin sensitivity, lowered blood pressure; reduction in oxidative stress and appetite in the evening. | Isocaloric intake | [182] |
Table 4. Cont.

| Participants | Eating Restrictions | Study Type/Duration | Health Outcomes                                                                 | Energy Intake                      | Reference |
|--------------|---------------------|---------------------|---------------------------------------------------------------------------------|-----------------------------------|-----------|
| n = 19 with metabolic syndrome | Eating over self-selected 10-h window | 2-week baseline intake, 12-week intervention | TRE improves cardiometabolic health (reduction in weight, BMI, waist circumference, percentage body fat, systolic and diastolic blood pressure, improved lipid parameters, glucose and insulin homeostasis) | Decreases caloric intake [183] |          |
| n = 8 overweight BMI > 25 kg/m² | Eating over self-selected 10-h window | 3-week baseline intake, 16-week | Reduction in body weight. Significant improvement in sleep, hunger at bedtime, energy levels | Reduced estimated energy intake by 20–26% [170] |          |
| n = 11, BMI 25.0 and 35.0 kg/m² | eTRF (8 am to 2 pm) vs. control (8 am to 8 pm) | Randomized crossover 4-day intervention, 3.5–5 weeks’ washout period between interventions | eTRF improves 24-hour glucose levels, alters lipid metabolism and expression of SIRT1 and LC3A (autophagy gene), BDNF (a neurotrophic factor promoting neuronal growth) and mTOR | Isocaloric intake [184] |          |
| n = 11 overweight BMI 25–35 kg/m² | eTRF (8 am–2 pm) vs. control (8 am–8 pm) | Randomized crossover 4-day intervention, 3.5–5 weeks’ washout period between interventions | Meal-timing interventions facilitate weight loss primarily by decreasing appetite rather than by increasing energy expenditure. eTRF may also increase fat loss by increasing fat oxidation. | Isocaloric [185] |          |
| n = 21 healthy adults BMI 29.6 ± 2.6 kg/m² | TRE (12 pm to 8 pm) vs. control eating habits with concomitant aerobic exercise for 8 weeks | Randomized, controlled trial | TRE individuals lost significantly more body mass (3.3% vs. 0.2%) and fat mass (9% vs. 3.3%). Lean mass increased but no significant difference between the groups. | Reduction in caloric intake in TRE (~300 kCal/day) [186] |          |
| n = 27 BMI 21.9–26.9 kg/m² | TRE included an elimination of caloric intake between 7 pm and 6 am vs. controls | Crossover 2-week intervention with one-week washout period | TRE led to a loss in small amount of body weight | Reduction in energy (~240 Kcal) and fat intake un TRE group [187] |          |
| Participants | Eating Restrictions | Study Type/Duration | Health Outcomes | Energy Intake | Reference |
|--------------|---------------------|---------------------|-----------------|--------------|-----------|
| n = 18 Body weight 79.0 ± 13.5 kg in control group and 87.4 ± 19.2 in TRE group | TRE (eating over any 4-h window between 4 pm and 12 pm on the four days a week when they exercised but ad libitum on days without exercise) vs. control without any restrictions | Randomized controlled trial 8 weeks | No significant loss of body weight, no adverse effect on lean mass retention or muscular improvements. | TRF reduced caloric intake by ~667 kCal a day | [188] |
| n = 13 BMI 20–39 kg/m² | TRF with delayed breakfast and advanced dinner by 1.5 h vs. controls with habitual eating patterns | 2-week baseline, 10 weeks’ intervention | No significant reduction in weight, but reduction in adiposity, fasting glucose observed | Reduction in energy intake in TRE group | [189] |
| n = 40 resistance-trained females Body weight 57.1 to 73.4 Kg | Control diet vs. TRF (12 pm–8 pm) vs. TRF+ a leucine metabolite β-hydroxy β-methyl butyrate (HMB) supplementation | randomized, placebo-controlled for 8 weeks | TRF did not produce changes in physiological variables including resting metabolic rate, substrate utilization, blood lipids, glucose and insulin, blood pressure, arterial stiffness, or cortisol responses. No significant difference in physical performance. | No significant variation between the groups | [190] |
| n = 40 with abdominal obesity BMI 25.1–37.6 kg/m² | TRF eating window 8–9 h | 3-month single arm trial | Moderate weight loss, improved waist circumference, HbA1C | No data available | [191] |
| n = 22 men BMI: 28.5 ± 8.3 kg/m² | Isocaloric TRF (8-h eating window, caloric intake within 300 Kcal of habitual intake) vs. ad libitum TRF (8-h eating window but no restriction on calories) | 28 days randomised control trial | Decrease in body mass, decrease in fat body mass, decrease in BP and increase in HDLC in both groups. | No significant difference in caloric intake | [192] |
| n = 20 obese BMI 34.1± 7.5 kg/m² | TRE (self-selected 8-h eating window) vs. control on ad libitum | 12 weeks | Decrease in eating frequency, weight, lean mass, visceral fat | No data reported | [193] |
| n = 116 overweight and obese BMI 27.4–35.4 kg/m² | TRE (12–8 pm) eating vs. ad libitum | 12 weeks’ randomised control trial | Loss of body weight in TRE group | No significant difference in caloric intake | [194] |
| Participants | Eating Restrictions | Study Type/Duration | Health Outcomes | Energy Intake | Reference |
|--------------|---------------------|---------------------|-----------------|--------------|-----------|
| n = 271 NAFLD BMI > 24 kg/m² | Control vs. ADF (25% energy intake on fast days) vs. TRF (self-directed 8-hour window) | 12 weeks’ randomised control trial | Significant weight loss and fat mass loss, reduction in cholesterol and triglycerides both in ADF and TRF with ADF achieving better outcomes | No significant difference in caloric intake | [195] |
| n = 15 PCOS women BMI ≥ 24 kg/m² | TRE (8 am–4 pm) | Non-randomized 1 week baseline, 5 weeks’ intervention | Reduction in body weight, BMI, body fat mass, body fat percentage, improved insulin sensitivity | Isocaloric | [196] |
| n = 22 BMI = 24.7 ± 0.6 kg/m² | TRE (eating within 8-h window but first meal between 10–11 am) vs. controls with normal feeding patterns | Randomized controlled trial, 1 week baseline, 6-week intervention | No weight loss or improvement in cardiovascular function with modest improvement in functional endurance and glucose tolerance, 84–95% adherence | Isocaloric | [197] |
| n = 60 BMI ≥ 30 kg/m² | 14:10 TRE (14-h metabolic fast with snack with 200 kcal mixed nuts 12 h after the fast started) vs. 12:12 TRE (12-h fast without any snack) | Randomized controlled trial 8 weeks intervention | Weight loss observed in both cases but more in 14 h metabolic fast group, improved fasting blood glucose. Fasting snack decreased hunger | 500–1000 kcal deficit each day | [198] |
| n = 45 with at least one metabolic syndrome component and usual eating window of 14 h. BMI ≥ 20 kg/m² | TRE (self-selected window of 12 h) vs. no restriction | Randomised control trial 4 weeks’ baseline, 6-month intervention | No significant difference in weight loss | No difference reported | [199] |
| n = 80 males | TRF (8-h eating window, 7.30 pm–3.30 am) vs. normal diet daily fasting for 16 h for 25 days | 25 Days | TRF improved lipid parameters, reduced inflammatory markers, enhanced gut microbial richness with enrichment of Prevotellaceae and Bacteroidaceae; activated SIRT1 | No data available | [200] |
### Table 4. Cont.

| Participants | Eating Restrictions | Study Type/Duration | Health Outcomes | Energy Intake | Reference |
|--------------|---------------------|---------------------|-----------------|--------------|-----------|
| **N = 16 BMI 24.0 ± 0.6 kg/m²** | eTRF (8 am till 4 pm) vs. control on caloric restriction | Non-randomised 1-week baseline, 2 weeks’ intervention | eTRF improved insulin sensitivity, glucose uptake, reduction in energy intake and weight loss | Isocaloric | [201] |
| **N = 37 overweight BMI 26.4–28.55 kg/m²** | TRE (8 am–4 pm) vs. BMI matched participants on hypocaloric diet based on orthodox fasting | Both groups showed reduction in BMI and fasting group also showed a reduction in total and LDL cholesterol | Isocaloric | [202] |
| **N = 15 men at risk of T2D BMI 33.9 ± 0.8 kg/m²** | eTRF (8 am–5 pm) vs. late TRF (12 pm–9 pm) over 2-time 7-day TRF with 2 weeks’ washout period | Randomised crossover trial, 1-week baseline, 1-week intervention, 2 weeks’ washout period | Both TRF regimens showed reductions in body weight, glycaemic responses to a test meal, triglycerides. | No data available | [203] |
| **N = 82 BMI 18.6–25.8 kg/m²** | Early TRF (6 am–3 pm) vs. mid-day TRF (11 am–8 pm) vs. controls | Randomised control trial, 5 weeks’ intervention | Early TRF was more effective in improving insulin sensitivity, fasting glucose, reduction in body mass and adiposity, reduction in inflammation and increased gut microbial diversity | Reduction in caloric intake in both TRF groups vs. control | [204] |
| **N = 8 prediabetic BMI 32.2 ± 4.4 kg/m²** | eTRF (6-h eating window and dinner before 3 pm) vs. 12-h eating period | Randomised crossover trial, 5 weeks’ intervention with a 7-week washout period | eTRF reduced insulin levels and improved insulin sensitivity, lowered blood pressure, reduction in oxidative stress and appetite in the evening. | Isocaloric | [181] |
| **N = 93 Overweight and obese women BMI 32.4 ± 1.8 kg/m²** | 1440 KCal consumed over breakfast/lunch/dinner 700, 500, 200 kcal vs. 200,500, 700 kcal | Randomized parallel-arm study for 12 weeks. | High caloric breakfast group showed greater weight loss and waist circumference, fasting glucose, insulin, triglycerides, HOMA-IR. Ghrelin, hunger vs satiety improved. | | [205] |
| **N = 1245 non-obese, non-diabetic middle-aged adults** | Daily caloric intake at dinner (<33% vs. 33–48 vs. ≥48% of daily kcal) | 6 years | Consuming more calories at dinner is associated with an increased risk of obesity, metabolic syndrome and NAFLD | | [206] |

*TRF (time-restricted feeding), TRE (time-restricted eating), NAFLD (non-alcoholic fatty liver disease), HOMA-IR (homeostatic model assessment for insulin resistance), HbA1C (haemoglobin A1C), BDNF (brain-derived neurotrophic factor).*
5. Time-Restricted Eating—Just Another Approach to Reduce Caloric Intake or a Circadian Alignment Tool

The role of calorie consumption in energy homeostasis is not disputed, and creating a negative energy balance is a logical approach to tilt the scales. Calorie restriction (CR) refers to a consistent dietary regimen low in calories, generally a daily 20–40% reduction as compared with ad libitum feeding, without malnutrition (Figure 3). This is not simply another term for fasting, which is commonly defined as the total abstinence from energy-containing foods and beverages for periods ranging from 12 h to 3 weeks, although some protocols employ modified fasting in which a minimal number of calories may be consumed [207]. CR is one of the most effective interventions for weight loss, improving health parameters in animals including primates and is a highly successful strategy for reducing age-related diseases and extending the mean and maximum lifespan in multiple species [208–210]. In addition to animal studies including mice and monkeys, CR over a 6-year period in a cohort of 18 participants showed improved BMI, glucose homeostasis and lipid profile and reduced inflammatory markers and blood pressure [211–213]. Although short-term caloric restriction is associated with 5–10% weight loss, long-term compliance is a massive challenge and there is a tendency to regain the lost weight [214,215]. To overcome these challenges, alternative dietary strategies such as intermittent caloric restriction have gained attention.

Figure 3. Dietary weight-loss approaches. Continuous caloric restriction includes reducing caloric intake on each day of the week but does not restrict time of the day. Intermittent fasting, e.g., 5:2 diet, introduces two caloric restriction days with ad libitum eating for the rest of the week. Time-restricted feeding limits the eating window and extended fast period regularly.

The intermittent fasting (IF) approach involves introducing intermittent periods of eating deprivation, providing a less restrictive alternative to CR. The regimen includes periods of fasting where the energy restriction ranges from 60–100%, interrupted by periods of normal dietary intake (isocaloric/ad libitum). This approach is adopted in a variety of protocols; alternate day fasting (no calories on fasting day and ad libitum on feast days), alternate-day modified fasting (consuming <25% of usual caloric intake on fasting days and ad libitum on feast days), 5:2 diet (with 2 days of fasting with 60–100% energy restrictions and 5 days of isocaloric intake), 4:3 (with 3 days of fasting with 60–100% energy restrictions and 4 days of isocaloric intake) (Figure 3) [214,216–218]. Certain religious fasting practices observed including the Islamic month of Ramadan have been studied as part of IF approaches [219]. This approach, as compared to continuous CR, introduces periods of fasting when the metabolism shifts towards the catabolic state and mimics the feast/fast physiology of our hunter-gatherer past [220]. Even though the IF regimen
suggests ad libitum feeding on non-fasting days, there is no full compensation for the
fasting days/time, and overall there is an energy deficit or lack of calories. Various studies
have compared IF approaches to continuous CR and reported comparable or better weight
loss and improvement in metabolic health [189,221–228].

Time-restricted feeding (TRF) is considered a modified version of IF, where the energy
intake is limited to a window of 4 to 12 h in order to extend the time spent in the fasted
state regularly, without changes in caloric intake (Figure 3) [229]. Even though caloric
restriction is not intentional in TRF, multiple studies have reported that restricting the
feeding window to 8 h produces a mild caloric deficit [176,179]. In fact, any restriction to
the eating window helps reduce the energy intake, e.g., just stopping night-time eating in
healthy individuals leads to a reduction in energy intake [187]. Considering the deleterious
effects of chronodisruption, extended eating duration and the imbalanced spread of energy
intake during the day, it is clear that the timing of a meal is instrumental in fine tuning
the energy balance. Thus, TRF is more than just a mode for caloric restriction or IF; it also
synchronises the feeding time with the awake/active phase when the body is best able
to metabolise it. More recently, the health-promoting role of caloric restriction has been
shown to be partly due to TRF rather than just caloric intake and extended periods of
fasting independent of caloric content share the same if not better health outcomes [230].
This leads to an alignment of the feeding-fasting cycle with circadian rhythms and offers
a promising dietary strategy to mitigate the deleterious effect of chronodisruption [231].
Mice fed with a high-fat diet showed a dampened diurnal rhythm in physiology, which
was recovered in the cohort on same diet but over a time-restricted period [232]. There is
a plethora of research supporting TRF being beneficial in not only reducing body weight
but also improving metabolic health in general (Table 4) [184,204,231–234]. Interestingly, as
well as the length of the restriction window, the timing of the TRF within the 24-hour cycle
is important and may provide slightly different outcomes. Restricting the feeding period
to earlier in the day (eTRF) provides advantageous outcomes than mid-day TRF (mTRF)
or later TRF (lTRF), as this aligns better with circadian biology, though larger studies and
more data are required to fine-tune the interventions [204]. Attempts have also been made
to have a pragmatic approach to adapt TRF approaches to life/work schedules. It has
been shown that TRF for 8–9 h a day for 5 days and ad libitum for 2 days, still reverses or
restricts diet-induced obesity [235,236].

Caloric restriction and intermittent fasting are not strictly part of the chrononutrition
strategy, as the focus is not about aligning meal times with the biological clock. However,
due to the common mechanisms of an overall negative energy balance, which is involuntary
in IF and TRF, they share certain molecular mechanisms that contribute to the overall energy
homeostasis. Each of the above-mentioned strategies have challenges and potential barriers
to adherence for a long-term weight-loss strategy, though the current view supports TRF as
a promising tool with greater-than-ordinary adherence, a good safety profile, and socially
acceptable flexible implementation [237–240].

6. Mechanisms of Chrononutrition in Energy Homeostasis and Obesity
6.1. Appetite Control

Appetite, eating behaviour, hunger/satiety and energy homeostasis are controlled by
the melanocortin system. This includes melanocortin receptor 4 (MC4R), which is present
in the brain and is activated by its ligand, melanocyte-stimulating hormone (MSH). MSH
is produced by the arcuate nucleus (ARC) in the hypothalamus that consists of two dis-
tinct types of neurons: anorexigenic neurons expressing proopiomelanocortin (POMC) the
orexigenic neurons expressing NeuroPeptide-Y (NPY) and agouti-related protein (AgRP),
having opposite effects on energy homeostasis. Leptin, an adipocyte-derived satiety hor-
mon, activates POMC neurons, and its circulatory levels directly relate to adiposity. This
results in the proteolytic conversion of POMC and the release of α-MSH, which activates
MC4R, promoting satiety, reduced food intake and increased energy expenditure. Leptin
also binds to AgRP neurons, resulting in the suppression of AgRP release, which is a potent
Leptin and ghrelin levels both exhibit diurnal oscillations and are influenced by obesity and food intake [245–249]. Circulating leptin levels peak at night and are lowest in the afternoon, but in obese subjects the amplitude in these oscillations is lost [249]. Circadian disruption abolishes circadian oscillation patterns of plasma leptin and induces leptin resistance [104,247,250]. Leptin is high in obese subjects, but, due to leptin resistance, the satiety signal is absent/compromised. Diets rich in fat inhibit the anorectic effects of leptin while sucrose- and fructose-rich diets promote leptin resistance [251,252]. Fasting leads to a drop in leptin levels and intermittent fasting improves leptin resistance. [253–256]. Leptin also regulates energy homeostasis through AMP-activated protein kinase (AMPK) by increasing fatty acid oxidation and reducing fatty acid biosynthesis [257,258]. Leptin also increases the expression of uncoupling protein-1 (UCP1) and the browning of white adipose tissue and thermogenesis, discussed later in this section [259]. GLPI and PYY are under the control of clock machinery and exhibit circadian patterns of rhythmicity [260,261].
Ghrelin levels increase during fasting or just before the habitual feeding time, dropping postprandially. Overweight and obese subjects lose this variation with a lesser drop in postprandial ghrelin levels leading to lower level of satiety after a meal, promoting snacking and overconsumption of food [262]. Ghrelin levels increase in response to caloric restriction and remain high for a considerable length of time, leading to increased food intake and regaining weight [263–265]. The response of plasma ghrelin levels to time-restricted feeding are inconsistent, with some studies reporting its reduction, while others show no effect [182,185,266,267].

Sleep duration also regulates ghrelin and leptin levels in circulation and contribute to energy homeostasis [268–270]. Insufficient sleep possibly works via altering the levels of melatonin, which plays a key role in food intake and energy expenditure. Melatonin reduces the expression of AgRP/NPY and increases the expression of POMC, hence regulating energy homeostasis via the MC4R pathway in the hypothalamus. Melatonin also inhibits leptin secretion and ameliorates leptin resistance, which accompanies obesity [249]. Lack of sleep also interferes with the weight loss achieved by caloric restriction, indicating the key role of sleep in terms of the efficacy of weight-loss strategies [269]. TRF and multiple natural bioactive compounds have been associated with an improvement in sleep [76,271,272].

6.2. Energy Sensors in the Body
6.2.1. AMP-Activated Protein Kinase (AMPK)

AMP-activated protein kinase (AMPK) is the key energy sensor in the cell and has the ability to regulate whole-body metabolism. AMPK is activated upon a fall in intracellular ATP levels and increases in ADP or AMP levels, which reflects the energy status of the cell.

Upon activation, AMPK switches on the catabolic pathways, leading to ATP generation and switching off the anabolic ATP-consuming pathways. ATP generation happens by promoting glycolysis and fatty acid oxidation and in the long term, by increasing mitochondrial content and the use of mitochondrial substrates as an energy source [273].

Fasting/intermittent fasting/nutritional deprivation activates AMPK, converting this nutritional signal to a circadian signal by phosphorylating CRY, resulting in its degradation. AMPK also phosphorylates casein kinase I epsilon, which in turn phosphorylates and degrades PER [274]. This removes repression on CLOCK-BMAL1, shortens the timing of the feedback loop and activates the transcription of the target genes including REV-ERBα, PER and CRY [275]. When a high-fat diet is administered ad libitum, this leads to a disturbed and dampened circadian rhythm of AMPK, while eTRF increases the amplitude of expression of AMPK [232,276].

One key target for activated AMPK is nicotinamide phosphoribosyltransferase (NAMPT), an enzyme that promotes an increase in intracellular levels of nicotinamide adenine dinucleotide (NAD\(^+\)) levels (Figure 4). NAD\(^+\) is essential for cellular energy maintenance and central to cell health. NAD\(^+\) acts as a redox carrier that gets converted to NADH in various metabolic pathways including glycolysis, the TCA cycle and fatty acid oxidation. NADH serves as the hydride donor to the electron-transport chain for the production of ATP in mitochondria. Additionally, NAD\(^+\) acts as a cofactor or co-substrate to enzymes such as sirtuins and poly (ADP-ribose) polymerases (PARPs). All these processes continuously deplete the NAD\(^+\) pool in the cell, which can be replenished by de novo pathway from tryptophan and the predominant salvage pathway from the NAD\(^+\) degradation product nicotinamide (NAM) [277]. In the salvage pathway, NAM is converted by NAMPT, the rate-limiting enzyme in the pathway, to an intermediate product, nicotinamide mononucleotide (NMN). NMN adenyltransferase 1-3 (NMNAT1-3) then converts NMN into NAD\(^+\) [278]. The CLOCK-BMAL1 complex binds to the E-boxes in the NAMPT promoter and controls its transcription and the levels display robust circadian oscillations providing a 24-h rhythm to NAD\(^+\) levels in the cell. NAD\(^+\) levels peak approximately 4 h after the peak in NAMPT [279,280]. NAD\(^+\) levels depend on cellular energy levels. Glucose deprivation, fasting, caloric restriction and exercise lead to an increase, and high-fat diets decrease NAD\(^+\) levels [281–283]. Fasting or calorie restriction increases cellular NAD\(^+\) levels by acti-
vating NAMPT and feeding suppresses NAMPT, providing a link between metabolism and the circadian clock [21,280,283,284]. Sirtuins and PARPs (poly (ADP-ribose) polymerases) depend on and compete for the cellular pool of NAD+. Cellular NAD+ stores are important for cell health, delay the onset of multiple diseases and enhance longevity, and lifestyle interventions that lead to increased NAD+ bioavailability are recommended for positive health outcomes [285].

Sirtuins (silencing information regulator) are a seven-member superfamily of proteins, which deacetylates histones and non-histone proteins and use NAD+ as a co-substrate, converting it into nicotinamide (NAM). The dependence of sirtuins on NAD+ suggests their role as energy sensors of the cell [286]. Studies over the past two decades have provided strong evidence that sirtuins are the key mediators of the beneficial effects of caloric restriction [287–291]. NAD+ levels are increased in fasting, intermittent fasting or caloric restriction, leading to the activation of sirtuins. Activated sirtuins deacetylate a number of proteins playing key roles in metabolism, inflammation, autophagy, aging, apoptosis, oxidative stress, neurodegeneration and cancer [286,292]. SIRT1, the most extensively studied sirtuin, interacts with the clock machinery contributing to the circadian rhythms. SIRT1 expression follows circadian patterns mainly due to circadian regulation of NAMPT and NAD+ levels. In turn, SIRT1 binds to the CLOCK-BMAL1 complex in a circadian manner and regulates clock-dependent gene expression and oscillations, NAMPT being one of them (Figure 1) [293,294]. CLOCK is an acetyltransferase and acetylates BMAL1, which results in the activation of the dimer while SIRT1 counterbalances CLOCK activity and deacetylates BMAL1. Additionally, SIRT1 also deacetylates PER2 and enhances its degradation. The absence of SIRT1 leads to PER2 stabilisation and the inhibition of CLOCK-BMAL1 activity, impacting the expression of various clock-dependent genes while PER2 negatively regulates SIRT1 [293–295]. SIRT1, playing a dual role as an energy sensor and a regulator of clock components, couples metabolism and circadian mechanisms. SIRT1 activation also leads to deacetylation and enhanced PGC1α transcriptional activation [273,297–299].

In addition to caloric restriction, multiple dietary polyphenols have been investigated for their health-promoting properties via activating sirtuins—resveratrol being the most extensively researched (Table 3) [300–302]. In fact, a new term has emerged for food components that modulate sirtuin activities mainly by increasing the bioavailability of NAD+: “Sirtfood” [303–306].

Although a vast amount of data is available connecting sirtuins and caloric restriction, fasting and intermittent fasting, the data on the link between the time-restricted feeding and sirtuins have only started to emerge. In mice, TRF has been shown to increase SIRT1 expression and reverse the loss of circadian rhythm in SIRT1 expression caused by a high-fat ad libitum diet [200,307]. Human studies indicate that restricting eating time to the earlier part of the day upregulates SIRT1 expression and the amplitude of SIRT1 circadian oscillations and associated health benefits [184,200].

PARPs (poly (ADP-ribose) polymerases) catalyse the transfer of poly (ADP-ribose) from NAD+ to acceptor proteins to modulate their activity and deplete the cellular NAD+ stores. PARP1 is the best characterised member and responsible for about 90% of the total cellular poly-ADP-ribosylation activity. PARP1 plays a critical active role in DNA repair, metabolism, inflammation and cell death [285,308,309]. PARP1 expression exhibits circadian patterns and poly-ADP-ribosylates and modulates the activities of CLOCK-protein-inhibiting CLOCK-BMAL1 binding activity in a circadian manner [24]. Fasting reduces while a high-fat diet increases PARP1 protein and its activity [310]. The knockdown or inhibition of PARP1 in mice leads to leaner phenotype, increased availability of NAD+, activation of SIRT1 and related metabolic effects, while the reverse was observed in the case of a PARP1 inducer [310]. Loss of PARP1 contributes to the browning of white adipose tissue, partly by activating SIRT1 and PPARγ [311–313].
6.2.2. Mitochondrial Dynamics

Mitochondria play a pivotal role in cellular metabolism by generating the basic unit of energy, ATP. Metabolic diseases such as obesity, a high-fat diet or excessive caloric intake all lead to mitochondrial dysfunction, which leads to energy deficiency and an increase in the production of reactive oxygen species, causing cell damage [314,315]. Cellular quality control processes including mitophagy and mitochondrial biogenesis ensure that mitochondrial capacity, function and integrity are preserved. Mitochondrial biogenesis is regulated by many transcriptional regulators present in the cell, PGC1α being the key one. PGC1α is an inducible transcriptional coactivator that regulates multiple transcription factors involved in energy metabolism and exhibits strong circadian rhythms in multiple tissues [316–319]. The activity of PGC1α is regulated by posttranslational modifications; the deacetylation and phosphorylation of PGC1α lead to its activation (Figure 4) [320,321].

Caloric restriction via fasting, intermittent fasting or time-restricted feeding leads to SIRT1 and AMPK activation, which leads to the deacetylation and phosphorylation of PGC1α, respectively; both these modifications activate PGC1α and an increased mitochondrial biogenesis [298,299,321–323]. The process of mitochondrial biogenesis is generally associated with improved cell health and has been reported in various cell types [324–326]. Inactive phase feeding in rats leads to an altered regulation of mitochondrial biogenesis [327]. Dietary interventions such as whole-grain bioactive compounds and various polyphenolic compounds also contribute to mitochondrial biogenesis, mainly via the SIRT-PGC1α pathway [328–330]. One of the tissues where mitochondrial biogenesis contributes to obesity and energy homeostasis is adipocytes.

6.2.3. Adipose Tissue

There are two distinct categories of adipose tissue, white adipose tissue (WAT) and brown adipose tissue (BAT). WAT stores energy in the form of triglycerides in times of caloric excess and is associated with metabolic disease states. BAT is rich in mitochondria and has a high expression of uncoupling protein-1 (UCP1), can uncouple fatty acid oxidation from ATP production and is specialized for energy expenditure via thermogenesis, modulating the energy homeostasis. It has a protective role in metabolic health. BAT can also protect against diet-induced obesity, and genetic variants in key genes involved in the process have been recognised to contribute to impaired thermogenesis [331,332]. In addition to classical WAT and BAT, trans-differentiation of WAT can lead to a beige or brite adipose tissue via a process called ‘browning’, with positive health outcomes. These beige cells start to express UCP1 accompanied by mitochondrial biogenesis leading to an increased mass of mitochondria (Figure 4). PGC1α, PPARγ and PRDM16 are the three key modulators of browning of WAT and all have been associated with circadian clocks [333–335]. PPARγ is a nuclear transcription factor and a nutrient sensor that plays critical roles in adipocyte differentiation. PPARγ exhibits circadian rhythmicity at mRNA and protein level. Nocturnin, a circadian-regulated gene also positively regulates PPARγ activity. PPARγ induces REV-ERBα expression and PER2 directly inhibits the expression of PPARγ [336]. PPARγ activation by synthetic ligands can upregulate browning in WAT and it requires the recruitment of PR (PRD1-BF1-RIZ1 homologous)-domain-containing 15 (PRDM16) to form the transcription complex. PRDM16 also induces the expression of PGC1α and UCP1 [337–339]. Additionally, the circadian components BMAL1, RORα and REV-ERBα also regulate BAT differentiation [335,340–342]. Thus, the modulation of the adipocyte phenotype to BAT contributes to enhanced energy homeostasis, and any strategy mediating this effect can positively contribute to health.

Caloric restriction and exercise contribute to PGC1α activation and associated health outcomes [343–348]. Aligning meal times with the circadian rhythms by time-restricted feeding in animal models can also modulate PGC1α activity and mitochondrial biogenesis. [323,349–353]. Additionally, various polyphenolic compounds contribute to mitochondrial biogenesis via PGC1α activation, which is mediated via AMPK-SIRT1 activation [354,355]. Sleep, melatonin and leptin pathways also contribute to the browning of
WAT and energy homeostasis via the induction of UCP1 expression and mitochondrial biogenesis (Figure 4) [249,259].

6.2.4. Gut Microbiota

One of the mechanisms for health benefits from chrononutrition is via modulation of the gut microbial community. The gut is not just the site of nutrient absorption, it is also the home to a vast, complex, diverse microbial community. The delicate balance in gut flora diversity and its species/phyla distribution is critical for host health. In addition to dietary components, circadian oscillations also influence the microbial composition and functional profile during the 24-h period. Chronodisruption, including CLOCK mutant models, leads to dysbiosis and promotes obesity, while fasting, intermittent fasting or time-restricted feeding help re-set the balance. Multiple mechanisms are involved between these complex interactions [356–359]. Firstly, the species distribution of the microbes varies significantly between obese and lean individuals. The two dominant divisions of bacteria in human gut are Firmicutes and Bacteroidetes, and an increased Firmicutes:Bacteroidetes ratio has been associated with obesity [360]. High-fat diets and feeding during the biological night led to an increase in Firmicutes, while caloric restrictions, intermittent fasting, time-restricted feeding, plant-based, high-fibre diets, green tea, cranberry extracts, quercetin, resveratrol and persimmon tannins normalise this ratio and contribute to weight loss (Figure 4) [307,359,361–367].

Secondly, the gut flora is not a passive and silent community with actions limited to the gut; they are metabolically active and release metabolites into the gut, which are absorbed, enter host circulation and contribute to host physiology, including nutrient sensing. The dietary components and dietary patterns both define the microbial diversity, species distribution and microbial metabolites and have been linked to BMI, glucose homeostasis, metabolic disorders, several inflammatory and cardiovascular diseases, intestinal health, bio-activation of nutrients and vitamins, sleep disorders, neurodegenerative diseases and malignancy [368,369]. Plant-based diets, rich in fruit, vegetables, whole grains and polyphenols, promote microbial diversity, while Western diets, rich in fats and low in fibre, reduce gut microbial diversity [367]. One class of metabolites, called short-chain fatty acids (SC-FAs), play multiple roles, including the regulation of energy derived from food, reducing inflammation, preventing pathogen invasion and maintaining barrier integrity. These also act as ligands to G-protein coupled receptors (GPCRs), which, upon activation can lead to a variety of metabolic effects, including the stimulation of the secretion of insulin, glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which in turn, act to increase satiety and increase transit time [368–371]. Butyrate, a SCFA, also leads to AMPK activation and accompanying beneficial effects discussed above. Butyrate, a type of SCFA in the cecum of mice fed with regular chow, showed diurnal patterns with the ability to enhance the circadian gene amplitude in the liver, which was absent in high-fat-diet fed mice [372]. TRF and intermittent energy restriction caused the enrichment of species that upregulated the generation of SCFA [373]. The gut microbiota also contributes to the adipocyte phenotype and the expression of UCP1. Mice fed with a high-fat diet but over a limited feeding period showed an improved rhythmic expression of UCP1 and improved night-time energy consumption and oscillations in PPARα expression [232]. There is a reciprocal relationship between dietary polyphenols and the gut microbiota. Gut microbiota, as demonstrated by germ-free models, influence the metabolism and bioavailability of these compounds, while the health-promoting properties of polyphenols are partly mediated by their ability to act as a prebiotic to promote growth, reshape the microbial composition and reverse the disturbances in microflora caused by chronodisruption [137,163].

7. Conclusions

Obesity is a critical global public health threat that without urgent and multifaceted approaches will continue its inexorable rise. Diet and energy balance remain key targets for any weight-regulatory intervention, but their application to manage long-term body weight
have yielded limited success. The key to a successful dietary intervention requires sustained adherence with pragmatic implementation, such that there is minimal interference to day-to-day activities. Optimising circadian mechanisms via nutritional means is a valid and innovative approach to address energy balance. Additionally, educating and empowering the public to make informed lifestyle choices is key for sustainable behavioural changes. These modifications based on the appreciation of interactions between ‘what we eat’ and ‘when we eat’ can potentially prevent, delay the onset of and manage obesity. However, larger and longer human studies with clearly defined bioactive dietary components, timing of consumption, eating windows and energy content in genetically diverse populations are required before translating chrononutritional strategies into effective interventions for the general population.

**Funding:** This research received no external funding. The APC was funded by the Cardiff School of Sport and Health Sciences.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. World Health Organization. Obesity and Overweight. World Health Organization. 2021. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 16 September 2022).

2. Poirier, P.; Giles, T.D.; Bray, G.A.; Hong, Y.; Stern, J.S.; Pi-Sunyer, F.X.; Eckel, R.H. Obesity and Cardiovascular Disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 968–976. [CrossRef] [PubMed]

3. New WHO Report: Europe Can Reverse Its Obesity “Epidemic”. 2022. Available online: https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic (accessed on 16 September 2022.).

4. Jiang, P.; Turek, F.W. The endogenous circadian clock programs animals to eat at certain times of the 24-hour day: What if we ignore the clock? Physiol. Behav. 2018, 193, 211–217. [CrossRef]

5. Stenvers, D.J.; Jongejan, A.; Atiqi, S.; Vreijling, J.P.; Limonard, E.J.; Endert, E.; Baas, F.; Moerland, P.D.; Fliers, E.; Kalsbeek, A.; et al. Diurnal rhythms in the white adipose tissue transcriptome are disturbed in obese individuals with type 2 diabetes compared with lean control individuals. Diabetologia 2019, 62, 704–716. [CrossRef] [PubMed]

6. Loos, R.J.F.; Yeo, G.S.H. The genetics of obesity: From discovery to biology. Nat. Rev. Genet. 2021, 23, 1. [CrossRef] [PubMed]

7. grivas, T.B.; Savvidou, O.D. Melatonin the “light of night” in human biology and adolescent idiopathic scoliosis. Scoliosis 2007, 2, 6–14. [CrossRef]

8. Challet, E. Interactions between photic and nonphotic stimuli to synchronize the master circadian clock in mammals. Front. Biosci. 2003, 8, s246–s257. [CrossRef] [PubMed]

9. Takahashi, J.S. Transcriptional architecture of the mammalian circadian clock. Nat. Rev. Genet. 2016, 18, 164–179. [CrossRef] [PubMed]

10. Kim, Y.H.; Lazar, M.A. Transcriptional Control of Circadian Rhythms and Metabolism: A Matter of Time and Space. Endocr. Rev. 2020, 41, 707–732. [CrossRef] [PubMed]

11. Grivas, T.B.; Savvidou, O.D. Melatonin in the “light of night” in human biology and adolescent idiopathic scoliosis. Scoliosis 2007, 2, 6–14. [CrossRef]

12. Pandi-Perumal, S.R.; Smits, M.; Spence, W.; Srinivasan, V.; Cardinali, D.P.; Lowe, A.D.; Kayumov, L. Dim light melatonin onset (DLMO): A tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31, 1–11. [CrossRef]

13. Zisapel, N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br. J. Pharmacol. 2018, 175, 3190–3199. [CrossRef]

14. Becucci, G.; Pannain, S. Sleep and obesity. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 402–412. [CrossRef] [PubMed]

15. Bo, S.; Ciccone, G.; Durazzo, M.; Ghinamo, L.; Villois, P.; Canil, S.; Gambino, R.; Cassader, M.; Gentile, L.; Cavallero-Perin, P. Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. Int. J. Obes. 2011, 35, 1442–1449. [CrossRef] [PubMed]

16. Potter, G.D.M.; Skene, D.J.; Arendt, J.; Cade, J.E.; Grant, P.J.; Hardie, L.J. Circadian Rhythm and Sleep Disruption: Causes, Metabolic Consequences, and Countermeasures. Endocr. Rev. 2016, 37, 584–608. [CrossRef] [PubMed]

17. Buhr, E.D.; Takahashi, J.S. Molecular components of the Mammalian circadian clock. Handb. Exp. Pharmacol. 2013, 217, 3–27.

18. Mohawk, J.A.; Green, C.B.; Takahashi, J.S. Central and Peripheral Circadian Clocks in Mammals. Annu. Rev. Neurosci. 2012, 35, 445–462. [CrossRef]
19. Liu, A.C.; Tran, H.G.; Zhang, E.E.; Priest, A.A.; Walsh, D.K.; Kay, S.A. Redundant Function of REV-ERBα and β and Non-Essential Role for Bmal1 Cycling in Transcriptional Regulation of Intracellular Circadian Rhythms. *PLoS Genet.* 2008, 4, e1000023. [CrossRef]

20. Liu, C.; Li, S.; Liu, T.; Borjigin, J.; Lin, J.D. Transcriptional coactivator PGC-1α integrates the mammalian clock and energy metabolism. *Nature* 2007, 447, 477–481. [CrossRef]

21. Bass, J.; Takahashi, J.S. Circadian Integration of Metabolism and Energetics. *Science* 2010, 330, 1349–1354. [CrossRef][PubMed]

22. Canaple, L.; Rambaud, J.; Dhkissi-Benyahya, O.; Rayet, B.; Tan, N.S.; Michalik, L.; Delaunay, F.; Wahl, W.; Laudet, V. Reciprocal Regulation of Brain and Muscle Armt-Like Protein 1 and Peroxisome Proliferator-Activated Receptor α Defines a Novel Positive Feedback Loop in the Rodent Liver Circadian Clock. *Mol. Endocrinol.* 2006, 20, 1715–1727. [CrossRef][PubMed]

23. Masri, S.; Sassone-Corsi, P. Plasticity and specificity of the circadian epigenome. *Nat. Neurosci.* 2010, 13, 1324–1329. [CrossRef][PubMed]

24. Asher, G.; Reinke, H.; Altmeyer, M.; Gutierrez-Arcelus, M.; Hottiger, M.O.; Schibler, U. Poly(ADP-Ribose) Polymerase 1 Participates in the Phase Entrainment of Circadian Clocks to Feeding. *Cell* 2010, 142, 943–953. [CrossRef][PubMed]

25. Hirayama, J.; Sahar, S.; Grimaldi, B.; Tamaru, T.; Takamatsu, K.; Nakahata, Y.; Sassone-Corsi, P. CLOCK-mediated acetylation of BMAL1 controls circadian function. *Nature* 2007, 450, 1086–1090. [CrossRef][PubMed]

26. Doi, M.; Hirayama, J.; Sassone-Corsi, P. Circadian Regulator CLOCK Is a Histone Acetyltransferase. *Cell* 2006, 125, 497–508. [CrossRef][PubMed]

27. Mure, L.S.; Le, H.D.; Benegiamo, G.; Chang, M.W.; Rios, L.; Jillani, N.; Ngotho, M.; Kariuki, T.; Dhkissi-Benyahya, O.; Cooper, H.M.; et al. Diurnal transcriptomic atlas of a primate across major neural and peripheral tissues. *Science* 2021, 359, 6381. [CrossRef][PubMed]

28. Fuhr, L.; Abreu, M.; Pett, P.; Relógio, A. Circadian systems biology: When time matters. *Comput. Struct. Biotechnol. J.* 2015, 13, 417–426. [CrossRef][PubMed]

29. Li, J.; Nie, P.; Türck, C.W.; Wang, G.-Z. Gene networks under circadian control exhibit diurnal organization in primate organs. *Commun. Biol.* 2022, 5, 1–14. [CrossRef][PubMed]

30. Eckel-Mahan, K.; Sassone-Corsi, P. Metabolism and the Circadian Clock Converge. *Physiol. Rev.* 2014, 93, 107–135. [CrossRef][PubMed]

31. Kornmann, B.; Schaad, O.; Bujard, H.; Takahashi, J.S.; Schibler, U. System-Driven and Oscillator-Dependent Circadian Transcription in Mice with a Conditionally Active Liver Clock. O’Rahilly, S., editor. *PLoS Biol.* 2007, 5, e34. [CrossRef]

32. Peng, X.; Fan, R.; Xie, L.; Shi, X.; Dong, K.; Zhang, S.; Tao, J.; Xu, W.; Ma, D.; Chen, J.; et al. A Growing Link between Circadian Rhythms, Type 2 Diabetes Mellitus and Alzheimer’s Disease. *Int. J. Mol. Sci.* 2022, 23, 504. [CrossRef]

33. Ki, Y.; Ri, H.; Lee, H.; Yoo, E.; Choe, J.; Lim, C. Warming Up Your Tick-Tock: Temperature-Dependent Regulation of Circadian Clocks. The Neuroscientist: A Review. *J. Neurosci. Neurol. Psychiatry Clocks. The Neuroscientist: A Review.* 2015, 21, 503–518. [CrossRef][PubMed]

34. Saini, R.; Jaskolski, M.; Davis, S.J. Circadian oscillator proteins across the kingdoms of life: Structural aspects. *Nature* 2011, 477–481. [CrossRef][PubMed]

35. Kaldi, F.; Kowalski, M.; Davis, S.J.; Davis, J.A.; Zylka, M.J.; Schibler, U. BMAL1 controls circadian function. *Nature* 2007, 450, 11086–1090. [CrossRef][PubMed]

36. Molina-Montes, E.; Rodriguez-Barranco, M.; Ching-Lopez, A.; Artacho, R.; Huerta, J.M.; Amiano, P.; Lasheras, C.; Moreno-Iribas, C.; Jimenez-Zabala, A.; Chirlaque, M.D.; et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Chronobiol. Int.* 2012, 29, 1153–1175. [CrossRef][PubMed]

37. Adan, A.; Archer, S.N.; Hidalgo, M.P.; Di Milia, L.; Natale, V.; Randler, C. Circadian Typology: A Comprehensive Review. *Chronobiol. Int.* 2012, 29, 1153–1175. [CrossRef][PubMed]

38. Safran, R.L.; Ackley, D.; Auger, R.R.; Carskadon, M.A.; Wright, J.K.P.; Vitiello, M.V.; Zhdanova, I.V. Circadian Rhythm Sleep Disorders: Part II, Advanced Sleep Phase Disorder, Delayed Sleep Phase Disorder, Free-Running Disorder, and Irregular Sleep-Wake Rhythm. *Sleep* 2007, 30, 1484–1501. [CrossRef][PubMed]

39. Adan, A.; Archer, S.N.; Di Milia, L.; Natale, V.; Randler, C. Circadian Typology: A Comprehensive Review. *Chronobiol. Int.* 2012, 29, 1153–1175. [CrossRef][PubMed]

40. Taillard, J.; Philip, P.; Clauserat, B.; Capelli, A.; Coste, O.; Chaumet, G.; Sasagpe, P. Time course of neurobehavioral alertness during extended wakefulness of morning- and evening-type healthy sleepers. *Chronobiol. Int.* 2011, 28, 520–527. [CrossRef][PubMed]

41. Jones, C.R.; Huang, A.L.; Ptaček, L.J.; Fu, Y.-H. Genetic basis of human circadian rhythm disorders. *Exp. Neurol.* 2013, 243, 28–33. [CrossRef][PubMed]

42. Jones, S.E.; Lane, J.M.; Wood, A.R.; van Hees, V.T.; Tyrrell, J.; Beaumont, R.N.; Jeffries, A.R.; Dashti, H.S.; Hillsdon, M.; Ruth, K.S.; et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Nat. Commun.* 2019, 10, 343. [CrossRef][PubMed]

43. Valladares, M.; Obregon, A.M.; Chaput, J.-P. Association between genetic variants of the clock gene core and obesity and sleep duration. *J. Physiol. Biochem.* 2015, 71, 855–860. [CrossRef][PubMed]

44. Ashbrook, L.H.; Krystal, A.D.; Fu, Y.-H.; Ptaček, L.J. Genetics of the human circadian clock and sleep homeostat. *Neuropsychopharmacology* 2019, 45, 45–54. [CrossRef][PubMed]

45. Reutrakul, S.; Hood, M.M.; Crowley, S.J.; Morgan, M.K.; Teodori, M.; Knutson, K.L.; Van Cauter, E. Chronotype Is Independently Associated with Glycemic Control in Type 2 Diabetes. *Diabetes Care* 2013, 36, 2523–2529. [CrossRef][PubMed]

46. Patterson, F.; Malone, S.K.; Grandner, M.A.; Lozano, A.; Perkett, M.; Hanlon, A. Interactive effects of sleep duration and morning/evening preference on cardiovascular risk factors. *Eur. J. Public Health* 2017, 28, 155–161. [CrossRef][PubMed]

47. Li, W.; Wu, M.; Yuan, F.; Zhang, H. Sugary beverage consumption mediates the relationship between late chronotype, sleep duration, and weight increase among undergraduates: A cross-sectional study. *Environ. Health Prev. Med.* 2018, 23, 63. [CrossRef][PubMed]
48. Anothaisintawee, T.; Lertrattananon, D.; Thamakason, S.; Thakkinstian, A.; Reutrakul, S. The Relationship Among Morningness-Eveningness, Sleep Duration, Social Jetlag, and Body Mass Index in Asian Patients with Prediabetes. *Front. Endocrinol.* 2018, 9, 435. [CrossRef]  
49. Culnan, E.; Kloss, J.D.; Grandner, M. A prospective study of weight gain associated with chronotype among college freshmen. *Chronobiol. Int.* 2013, 30, 682–690. [CrossRef]  
50. Sun, X.; Gustat, J.; Bertisch, S.; Redline, S.; Bazzano, L. The association between sleep chronotype and obesity among black and white participants of the Bogalusa Heart Study. *Chronobiol. Int.* 2019, 37, 123–134. [CrossRef]  
51. Roenneberg, T.; Wirz-Justice, A.; Merrow, M. Life between Clocks: Daily Temporal Patterns of Human Chronotypes. *J. Biol. Rhythm.* 2003, 18, 80–90. [CrossRef]  
52. Mishima, K.; Tozawa, T.; Satoh, K.; Saitoh, H.; Mishima, Y. The 3111T/C polymorphism of Clock is associated with evening preference and delayed sleep timing in a Japanese population sample. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 2005, 133, 101–104. [CrossRef]  
53. Garaulet, M.; Corbalán, M.D.; Madrid, J.A.; Morales, E.; Baraza, J.C.; Lee, Y.C.; Ordovas, J.M. CLOCK gene is implicated in weight reduction in obese patients participating in a dietary programme based on the Mediterranean diet. *Int. J. Obes.* 2010, 34, 516–523. [CrossRef]  
54. Monteleone, F.; Tortorella, A.; Docimo, L.; Maldonato, M.N.; Canestrelli, B.; De Luca, L.; Maj, M. Investigation of 3111T/C polymorphism of the CLOCK gene in obese individuals with or without binge eating disorder: Association with higher body mass index. *Neurosci. Lett.* 2008, 435, 30–33. [CrossRef]  
55. Lopez-Guimerà, G.; Dashi, H.S.; Smith, C.E.; Sánchez-Carracedo, D.; Ordovas, J.M.; Garaulet, M. CLOCK 3111 T/C SNP Interacts with Emotional Eating Behavior for Weight-Loss in a Mediterranean Population. Rosenfeld CS, editor. *PLoS ONE* 2014, 9, e99152. [CrossRef]  
56. Giovannini, N.P.; Fuly, J.T.; Moraes, L.I.; Coutinho, T.N.; Trarbach, E.B.; de L Jorge, A.A.; Costalonga, E.F. Study of the association between 3111T/C polymorphism of the CLOCK gene and the presence of overweight in schoolchildren. *J. Pediatr.* 2014, 90, 500–505. [CrossRef] [PubMed]  
57. Bandín, C.; Martínez-Nicolás, A.; Ordovás, J.M.; Lucas, J.A.R.; Castell, P.; Silvente, T.; Madrid, J.A.; Garaulet, M. Differences in circadian rhythmicity in CLOCK 3111T/C genetic variants in moderate obese women as assessed by thermometry, actimetry and body position. *Int. J. Obs.* 2012, 37, 1044–1050. [CrossRef] [PubMed]  
58. Garaulet, M.; Sánchez-Moreno, C.; Smith, C.E.; Lee, Y.-C.; Nicolás, F.; Ordovás, J.M. Ghrelin, Sleep Reduction and Evening Preference: Relationships to CLOCK 3111 T/C SNP and Weight Loss. Tomé D, editor. *PLoS ONE* 2011, 6, e17435. [CrossRef]  
59. Garcia-Rios, A.; Gomez-Delgado, F.J.; Garaulet, M.; Alcala-Diaz, J.F.; Delgado-Lista, F.J.; Marin, C.; Rangel-Zuñiga, O.A.; Rodriguez-Cantalejo, F.; Gomez-Luna, P.; Ordovas, J.M.; et al. Beneficial effect of CLOCKgene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. *Chronobiol. Int.* 2013, 31, 401–408. [CrossRef]  
60. Sookoian, S.; Gemma, C.; Gianotti, T.F.; Burgueño, A.; Castaño, G.; Pirola, C.J. Genetic variants of Clock transcription factor are associated with individual susceptibility to obesity. *Am. J. Clin. Nutr.* 2008, 87, 1606–1615. [CrossRef]  
61. Garaulet, M.; Lee, Y.-C.; Shen, J.; Parnell, L.D.; Arnett, D.K.; Tsai, M.Y.; Lai, C.-Q.; Ordovas, J.M. Genetic variants in human CLOCK associate with total energy intake and cytokine sleep factors in overweight subjects (GOLDN population). *Eur. J. Hum. Genet.* 2009, 18, 364–369. [CrossRef]  
62. Cambor Murube, M.; Borregón-Rivilla, E.; Colmenarejo, G.; Aguilar-Aguilar, E.; Martínez, J.A.; Ramírez De Molina, A.; Reglero, G.; Loria-Kohen, V. Polymorphism of CLOCK Gene rs3749474 as a Modulator of the Circadian Evening Carbohydrate Intake Impact on Nutritional Status in an Adult Sample. *Nutrients* 2020, 12, 1142. [CrossRef]  
63. Ye, D.; Cai, S.; Jiang, X.; Ding, Y.; Chen, K.; Fan, C.; Jin, M. Associations of polymorphisms in circadian genes with abdominal obesity in Chinese adult population. *Obes. Res. Clin. Pract.* 2016, 10 (Suppl. 1), S133–S141. [CrossRef] [PubMed]  
64. Scott, E.M.; Carter, A.M.; Grant, P.J. Association between polymorphisms in the Clock gene, obesity and the metabolic syndrome in man. *Int. J. Obes.* 2008, 32, 658–662. [CrossRef] [PubMed]  
65. Corella, D.; Asensio, E.M.; Coltell, O.; Sorlí, J.V.; Estruch, R.; Martínez-González, M.A.; Salas-Salvadó, J.; Castaño, O.; Arós, F.; Lapetra, J.; et al. CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: Dietary modulation in the PREMID randomized trial. *Cardiovasc. Diabetol.* 2016, 15, 4. [CrossRef] [PubMed]  
66. Gomez-Delgado, F.; Garcia-Rios, A.; Alcala-Diaz, J.F.; Rangel-Zuñiga, O.; Delgado-Lista, J.; Yubero-Serrano, E.M.; Lopez-Moreno, J.; Tinahones, F.J.; Ordovas, J.M.; Garaulet, M.; et al. Chronic consumption of a low-fat diet improves cardiometabolic risk factors according to the CLOCKgene in patients with coronary heart disease. *Mol. Nutr. Food Res.* 2015, 59, 2556–2564. [CrossRef] [PubMed]  
67. Garaulet, M.; Lee, Y.-C.; Shen, J.; Parnell, L.D.; Arnett, D.K.; Tsai, M.Y.; Lai, C.-Q.; Ordovas, J.M. CLOCK gene variation and metabolic syndrome risk: Modulation by monounsaturated fatty acids. *Am. J. Clin. Nutr.* 2009, 90, 1466–1475. [CrossRef] [PubMed]  
68. Dashti, H.S.; Follis, J.L.; Smith, C.E.; Tanaka, T.; Cade, B.E.; Gottlieb, D.J.; Hruby, A.; Jacques, P.F.; Lamon-Fava, S.; Richardson, K.; et al. Habitual sleep duration is associated with BMI and macronutrient intake and may be modified by CLOCK genetic variants. *Am. J. Clin. Nutr.* 2015, 101, 135–143. [CrossRef]
94. Damiola, F. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. *Genes Dev.* 2000, 14, 2950–2961. [CrossRef] [PubMed]

95. Baron, K.G.; Reid, K.J.; Kern, A.S.; Zee, P.C. Role of Sleep Timing in Caloric Intake and BMI. *Obesity* 2011, 19, 1374–1381. [CrossRef] [PubMed]

96. Yoshida, J.; Eguchi, E.; Nagoaka, K.; Ito, T.; Ogino, K. Association of night eating habits with metabolic syndrome and its components: A longitudinal study. *BMC Public Health* 2018, 18, 1366. [CrossRef] [PubMed]

97. Okada, C.; Imano, H.; Muraki, I.; Yamada, K.; Iso, H. The Association of Having a Late Dinner or Bedtime Snack and Skipping Breakfast with Overweight in Japanese Women. *J. Obes.* 2019, 2019, 2439571. [CrossRef] [PubMed]

98. Martinez-Lozano, N.; Tvarijonaviciute, A.; Rios, R.; Barón, I.; Scheer, F.A.J.L.; Garaulet, M. Late Eating Is Associated with Obesity, Inflammatory Markers and Circadian-Related Disturbances in School-Aged Children. *Nutrients* 2020, 12, 2881. [CrossRef]

99. Adnan, D.; Trinh, J.; Bishehsari, F. Inconsistent eating time is associated with obesity: A prospective study. *EXCLI J.* 2022, 21, 300–306.

100. Olds, T.S.; Maher, C.A.; Matricciani, L. Sleep Duration or Bedtime? Exploring the Relationship between Sleep Habits and Weight Status and Activity Patterns. *Sleep* 2011, 34, 1299–1307. [CrossRef]

101. Arora, T.; Taheri, S. Associations among late chronotype, body mass index and dietary behaviors in young adolescents. *Int. J. Obes.* 2014, 39, 39–44. [CrossRef] [PubMed]

102. Xiao, Q.; Garaulet, M.; Scheer, F.A.J.L. Meal timing and obesity: Interactions with macronutrient intake and chronotype. *Int. J. Obes.* 2019, 43, 1701–1711. [CrossRef] [PubMed]

103. Morris, C.J.; Purvis, T.E.; Hu, K.; Scheer, F.A.J.L. Circadian misalignment increases cardiovascular disease risk factors in humans. *Proc. Natl. Acad. Sci. USA* 2016, 113, E1402–E1411. [CrossRef] [PubMed]

104. Scheer, F.A.J.L.; Hilton, M.F.; Mantzoros, C.S.; Shea, S.A. Adverse metabolic and cardiovasculat consequences of circadian misalignment. *Proc. Natl. Acad. Sci. USA* 2009, 106, 4453–4458. [CrossRef] [PubMed]

105. Zhao, I.; Bogossian, F.; Song, S.; Turner, C. The Association Between Shift Work and Unhealthy Weight. *J. Occup. Environ. Med.* 2011, 53, 153–158. [CrossRef] [PubMed]

106. Guo, Y.; Rong, Y.; Huang, X.; Lai, H.; Luo, X.; Zhang, Z.; Liu, Y.; He, M.; Wu, T.; Chen, W. Shift Work and the Relationship with Metabolic Syndrome in Chinese Aged Workers. *PloS ONE* 2015, 10, e0120632. [CrossRef]

107. Kubo, T.; Oyama, I.; Nakamura, T.; Shirane, K.; Otsuka, H.; Kunimoto, M.; Kadowaki, K.; Maruyama, T.; Otomo, H.; Fujino, Y.; et al. Retrospective cohort study of the risk of obesity among shift workers: Findings from the Industry-based Shift Workers’ Health study. *Japan. Occup. Environ. Med.* 2010, 68, 327–331. [CrossRef]

108. Canuto, R.; Pattussi, M.P.; Macagnan, J.B.A.; Henn, R.L.; Olinto, M.T.A. Sleep deprivation and obesity in shift workers in southern Brazil. *Public Health Nutr.* 2013, 17, 2619–2623. [CrossRef] [PubMed]

109. Brum, M.C.B.; Dantas Filho, F.F.; Bertoletti, O.A.; Bottega, G.B.; da Costa Rodrigues, T. Night shift work, short sleep and obesity. *Diabetol. Metab. Syndr.* 2020, 12, 13. [CrossRef]

110. Hulsegge, G.; Proper, K.I.; Loef, B.; Paagman, H.; Anema, J.R.; van Mechelen, W. The mediating role of lifestyle in the relationship between shift work, obesity and diabetes. *Int. Arch. Occup. Environ. Health* 2021, 94, 1287–1295. [CrossRef]

111. Halberg, N.; Henriksen, M.; Söderhamn, N.; Stallknecht, B.; Ploug, T.; Schjerling, P.; Dela, F. Effect of intermittent fasting and obesity Risk Depending on Genotypes of Circadian Components in Mouse Liver. *Cell Metab.* 2019, 30, 1701–1711. [CrossRef] [PubMed]

112. Mierziak, J.; Kostyn, K.; Boba, A.; Czemplik, M.; Kulma, A.; Wojtasik, W. Influence of the Bioactive Diet Components on the Gene Expression Regulation. *Nutrients* 2019, 12, 3673. [CrossRef]

113. Shon, J.; Han, Y.; Park, Y.J. Effects of Dietary Fat to Carbohydrate Ratio on Obesity Risk Depending on Genotypes of Circadian Genes. *Nutrients* 2022, 14, 478. [CrossRef] [PubMed]

114. Tognini, P.; Samad, M.; Kinouchi, K.; Liu, Y.; Hellbling, J.-C.; Moisan, M.-P.; Eckel-Mahan, K.L.; Baldi, P.; Sassone-Corsi, P. Reshaping circadian metabolism in the suprachiasmatic nucleus and prefrontal cortex by nutritional challenge. *Proc. Natl. Acad. Sci. USA* 2020, 117, 29904–29913. [CrossRef] [PubMed]

115. Mendoza, J.; Pèvet, P.; Challet, E. High-fat feeding alters the clock synchronization to light. *J. Physiol.* 2008, 586, 5901–5910. [CrossRef]

116. Tognini, P.; Samad, M.; Sato, T.; Chao, A.; Sato, S.; Koronowski, K.B.; Park, G.; Alam, Y.; Mejhert, N.; et al. Tryptophan metabolism is a physiological integrator regulating circadian rhythms. *Mol. Metab.* 2022, 64, 101556. [CrossRef]

117. Jeong, K.; He, B.; Nohara, K.; Park, N.; Shin, Y.; Kim, S.; Shimomura, K.; Koike, N.; Yoo, S.H.; Chen, Z. Dual attenuation of proteasomal and autophagic BMAL1 degradation in ClockA19/Δ mice contributes to improved glucose homeostasis. *Sci. Rep.* 2015, 5, 12801. [CrossRef] [PubMed]

118. Kohsaka, A.; Laposky, A.D.; Ramsey, K.M.; Estrada, C.; Joshu, C.; Kobayashi, Y.; Turek, F.W.; Bass, J. High-Fat Diet Disrupts Behavioral and Molecular Circadian Rhythms in Mice. *Cell Metab.* 2007, 6, 414–421. [CrossRef]

119. Barnea, M.; Madar, Z.; Froy, O. High-Fat Diet Delays and Fasting Advances the Circadian Expression of Adiponectin Signaling Components in Mouse Liver. *Endocrinology* 2009, 150, 161–168. [CrossRef]
148. Okada, Y.; Okada, M. Quercetin, caffeic acid and resveratrol regulate circadian clock genes and aging-related genes in young and old human lung fibroblast cells. *Mol. Biol. Rep.* 2020, 47, 1021–1032. [CrossRef]

149. Ribas-Latre, A.; Baselga-Escudero, L.; Casanova, E.; Arola-Arnal, A.; Salvadó, M.-J.; Bladé, C.; Arola, L. Dietary proanthocyanidins modulate BMAL1 acetylation, Namp expression and NAD levels in rat liver. *Sci. Rep.* 2015, 5, 10954. [CrossRef]

150. Jiang, P.; Xu, C.; Zhang, P.; Ren, J.; Mageed, F.; Wu, X.; Chen, L.; Zeb, F.; Feng, Q.; Li, S. Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK. *Int. J. Mol. Med.* 2016, 42, 1221–1226. [CrossRef]

151. Li, H.; Ke, H.C.; Lim, J.; Gelling, R.W.; Han, W. Green tea (-)-epigallocatechin-3-gallate counteracts daytime overeating induced by high-fat diet in mice. *Mol. Nutr. Food Res.* 2016, 60, 2565–2575. [CrossRef]

152. Mi, Y.; Qi, G.; Fan, R.; Ji, X.; Liu, Z.; Liu, X. EGCG ameliorates diet-induced metabolic syndrome associating with the circadian clock. *Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.* 2017, 1863, 1575–1589. [CrossRef]

153. He, B.; Nohara, K.; Park, N.; Park, Y.-S.; Guillery, B.; Zhao, Z.; Garcia, J.M.; Koike, N.; Lee, C.C.; Takahashi, J.S.; et al. The small molecule Nobiletin targets the molecular oscillator to enhance circadian rhythms and protect against metabolic syndrome. *Cell Metab.* 2016, 23, 610–621. [CrossRef] [PubMed]

154. Qi, G.; Guo, R.; Tian, H.; Li, L.; Liu, H.; Mi, Y.; Liu, X. Nobiletin protects against insulin resistance and disorders of lipid metabolism by reprogramming of circadian clock in hepatocytes. *Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids* 2018, 1863, 549–562. [CrossRef] [PubMed]

155. Shinozaki, A.; Misawa, K.; Ikeda, Y.; Haraguchi, A.; Kamagata, M.; Tahara, Y.; Shibata, S. Potent Effects of Flavonoid Nobiletin on Amplitude, Period, and Phase of the Circadian Clock Rhythm in PER2::LUCIFERASE Mouse Embryonic Fibroblasts. *PLoS ONE* 2017, 12, e0170904. [CrossRef] [PubMed]

156. Lellupitiyage Don, S.S.; Robertson, K.L.; Lin, H.-H.; Labriola, C.; Harrington, M.E.; Taylor, S.R.; Farkas, M.E. Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-dependent manner. *PLoS ONE* 2020, 15, e0236315. [CrossRef] [PubMed]

157. Kim, E.; Nohara, K.; Wirianto, M.; Escobedo, G.; Lim, J.; Morales, R.; Yoo, S.-H.; Chen, Z. Effects of the Clock Modulator Nobiletin on Circadian Rhythm Dysfunction Mouse Model. *Biomolecules* 2021, 11, 1004. [CrossRef]

158. Larkin, S.; Padgett, C.A.; Butter, J.T.; Mintz, J.D.; Fulton, D.J.; Stepp, D.W. The biological clock enhancer nobiletin ameliorates astrogliosis-associated neuroinflammation and disease hallmarks in an Alzheimer’s disease model. *PLoS ONE* 2017, 12, G387–G400. [CrossRef] [PubMed]

159. Wiartanto, M.; Wang, C.; Kim, E.; Koike, N.; Gomez-Gutierrez, R.; Nohara, K.; Escobedo, G., Jr.; Choi, J.M.; Han, C.; Yagita, K.; et al. The clock modulator Nobiletin mitigates astrogliosis-associated neuroinflammation and disease hallmarks in an Alzheimer’s disease model. *FASEB J.* 2019, 34, 1184–1196. [CrossRef] [PubMed]

160. Oyama, Y.; Bartman, C.M.; Gile, J.; Sehrt, D.; Eckle, T. The Circadian PER2 Enhancer Nobiletin Reverses the Detrimental Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury. *Curr. Pharm. Des.* 2018, 24, 3376–3383. [CrossRef]

161. Nohara, K.; Mallampalli, V.; Nemkov, T.; Wirianto, M.; Yang, J.; Ye, Y.; Sun, Y.; Han, L.; Esser, K.A.; Mileykovskaya, E.; et al. Nobiletin fortifies mitochondrial respiration in skeletal muscle to promote healthy aging against metabolic challenge. *Nat. Commun.* 2019, 10, 3923. [CrossRef]

162. Petrenko, V.; Gandasi, N.R.; Sage, D.; Tengholm, A.; Barg, S.; Dibner, C. In pancreatic islets from type 2 diabetes patients, the dampened circadian oscillators lead to reduced insulin and glucagon secretion. *Proc. Natl. Acad. Sci. USA* 2020, 117, 2484–2495. [CrossRef]

163. Guo, T.; Ho, C.-T.; Zhang, X.; Cao, J.; Wang, H.; Shao, X.; Pan, D.; Wu, Z. Oolong Tea Polyphenols Ameliorate Circadian Rhythm of Intestinal Microbiome and Liver Clock Genes in Mouse Model. *J. Agric. Food Chem.* 2019, 67, 11969–11976. [CrossRef] [PubMed]

164. Zhang, L.; Yan, R.; Wu, Z. Metagenomics analysis of intestinal flora modulatory effect of green tea polyphenols by a circadian rhythm dysfunction mouse model. *J. Food Biochem.* 2020, 44, e13430. [CrossRef] [PubMed]

165. Guo, R.; Zhao, B.; Wang, Y.; Wu, D.; Wang, Y.; Yu, Y.; Yan, Y.; Zhang, W.; Liu, Z.; Liu, X. Cichoric Acid Prevents Free-Fatty-Acid-Induced Lipid Metabolism Disorders via Regulating Bmal1 in HepG2 Cells. *J. Agric. Food Chem.* 2018, 66, 9667–9676. [CrossRef]

166. Numata, M.; Hirano, A.; Yamamoto, Y.; Yasuda, M.; Miura, N.; Sayama, K.; Shibata, M.A.; Asai, T.; Oku, N.; Miyoshi, N.; et al. Metastasis of Breast Cancer Promoted by Circadian Rhythm Disruption due to Light/Dark Shift and its Prevention by Dietary Quercetin in Mice. *J. Circadian Rhythm.* 2021, 19, 2. [CrossRef] [PubMed]

167. Al Abdi, T.; Andreou, E.; Papageorgiou, A.; Haraclides, A.; Philippou, E. Personality, Chrono-nutrition and Cardiometabolic Health: A Narrative Review of the Evidence. *Advs. Nutr.* 2020, 11, 1201–1210. [CrossRef]

168. Lee, J.Y.; Lee, M.S.; Lee, J.S.; Halberg, F.E.; Halberg, J.; Schwartzkopff, O.; Cornèlissen, G. A Tribute to Franz Halberg, MD. *Hypertension* 2015, 66, 1090–1092. [CrossRef]

169. Cornelissen, G. When You Eat Matters: 60 Years of Franz Halberg’s Nutrition Chronomics. *Open Nutraceuticals J.* 2012, 5, 16–44. [CrossRef]

170. Doi, R.; Oishi, K.; Ishida, N. CLOCK Regulates Circadian Rhythms of Hepatic Glycogen Synthesis through Transcriptional Activation ofGys2. *J. Biol. Chem.* 2010, 285, 22114–22121. [CrossRef]

171. Ruddick-Collins, L.C.; Morgan, P.J.; Johnstone, A.M. Mealtime: A circadian disruptor and determinant of energy balance? *J. Neuroendocrinol.* 2020, 32, e12886. [CrossRef]
195. Cai, H.; Qin, Y.-L.; Shi, Z.-Y.; Chen, J.-H.; Zeng, M.-J.; Zhou, W.; Chen, R.-Q.; Chen, Z.-Y. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: A randomised controlled trial. BMC Gastroenterol. 2019, 19, 219. [CrossRef] [PubMed]

196. Li, C.; Xing, C.; Zhang, J.; Zhao, H.; Shi, W.; He, B. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. J. Transl. Med. 2021, 19, 148. [CrossRef]

197. Martens, C.R.; Rossman, M.J.; Mazzo, M.R.; Jankowski, L.R.; Nagy, E.E.; Denman, B.A.; Richey, J.J.; Johnson, S.A.; Ziembba, B.P.; Wang, Y.; et al. Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults. GeroScience 2020, 42, 667–686. [CrossRef]

198. Peeke, P.M.; Greenway, F.L.; Billes, S.K.; Zhang, D.; Fujioka, K. Effect of time restricted eating on body weight and fasting glucose in participants with obesity: Results of a randomized, controlled, virtual clinical trial. Nutr. Diabetes 2021, 11, 6. [CrossRef]

199. Phillips, N.; Mareschal, J.; Schwab, N.; Manoogian, E.; Borloz, S.; Ostinelli, G.; Gauthier-Jaques, A.; Umwali, S.; Rodriguez, E.G.; Aebeler, D.; et al. The Effects of Time-Restricted Eating versus Standard Dietary Advice on Weight, Metabolic Health and the Consumption of Processed Food: A Pragmatic Randomised Controlled Trial in Community-Based Adults. Nutrients 2021, 13, 1042. [CrossRef]

200. Zeb, F.; Wu, X.; Chen, L.; Fatima, S.; Haq, I.-U.; Chen, A.; Majeed, F.; Feng, Q.; Li, M. Effect of time-restricted feeding on metabolic risk and circadian association with gut microbiome in healthy males. Br. J. Nutr. 2020, 123, 1216–1226. [CrossRef]

201. Jones, R.; Pabla, P.; Mallinson, J.; Nixon, A.; Taylor, T.; Bennett, A.; Tsintzas, K. Two weeks of early time-restricted feeding (eTRF) improves skeletal muscle insulin and anabolic sensitivity in healthy men. Am. J. Clin. Nutr. 2020, 112, 1015–1028. [CrossRef]

202. Karras, S.N.; Koufakis, T.; Adamidou, L.; Antonopoulou, V.; Karalazou, P.; Thesiadou, K.; Mitrofanova, E.; Mulrooney, H.; Petroczi, A.; Zebekakis, P.; et al. Effects of orthodox religious fasting versus combined energy and time restricted eating on body weight, lipid concentrations and glycaemic profile. Int. J. Food Sci. Nutr. 2020, 72, 82–92. [CrossRef]

203. Hutchison, A.T.; Regmi, P.; Manoogian, E.N.; Fleischer, J.G.; Wittert, G.A.; Panda, S.; Heilbronn, L.K. Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial. Obesity 2019, 27, 774–732. [CrossRef] [PubMed]

204. Xie, Z.; Sun, Y.; Ye, Y.; Hu, D.; Zhang, H.; He, Z.; Zhao, H.; Yang, H.; Mao, Y. Randomized controlled trial for time-restricted eating in healthy volunteers without obesity. Nat. Commun. 2022, 13, 1003. [CrossRef] [PubMed]

205. Jakubowicz, D.; Barnea, M.; Wainstein, J.; Froy, O. High Caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity 2013, 21, 2504–2512. [CrossRef] [PubMed]

206. Bo, S.; Musso, G.; Beccuti, G.; Fadda, M.; Gambino, R.; Gentile, L.; Durazzo, M.; Ghigo, E.; Cassader, M. Consuming More of Daily Caloric Intake at Dinner Predisposes to Obesity. A 6-Year Population-Based Prospective Cohort Study. Claret M, editor. PLoS ONE 2014, 9, e108467. [CrossRef] [PubMed]

207. do Nascimento Queiroz, J.; Macedo, R.C.O.; Tinsley, G.M.; Reischak-Oliveira, A. Time-restricted eating and circadian rhythms: The biological clock is ticking. Crit. Rev. Food Sci. Nutr. 2020, 61, 2863–2875. [CrossRef]

208. Froy, O. Metabolism and Circadian Rhythms—Implications for Obesity. Endocr. Rev. 2010, 31, 1–24. [CrossRef]

209. Most, J.; Tosti, V.; Redman, L.M.; Fontana, L. Calorie restriction in humans: An update. Ageing Res. Rev. 2017, 39, 36–45. [CrossRef]

210. Wing, R.R.; Blair, E.H.; Boron, P.; Marcus, M.D.; Watanabe, R.; Bergman, R.N. Caloric Restriction Per Se Is a Significant Factor in Atherosclerosis in Humans. Proc. Natl. Acad. Sci. USA 2004, 101, 6659–6663. [CrossRef]

211. Fontana, L.; Meyer, T.E.; Klein, S.; Holloszy, J.O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl. Acad. Sci. USA 2004, 101, 6659–6663. [CrossRef]

212. Colman, R.J.; Beasley, T.M.; Kemnitz, J.W.; Johnson, S.C.; Weindruch, R.; Anderson, R.M. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat. Commun. 2014, 5, 3557. [CrossRef]

213. Mattison, J.A.; Colman, R.J.; Beasley, T.M.; Allison, D.B.; Kemnitz, J.W.; Roth, G.S.; Ingram, D.K.; Weindruch, R.; de Cabo, R.; Anderson, R. Caloric restriction improves health and survival of rhesus monkeys. Nat. Commun. 2017, 8, 14063. [CrossRef] [PubMed]

214. Rynders, C.A.; Thomas, E.A.; Zaman, A.; Pan, Z.; Catenacci, V.A.; Melanson, E.L. Effectiveness of Intermittent Fasting and Time-Restricted Feeding Compared to Continuous Energy Restriction for Weight Loss. Nutrients 2019, 11, 2442. [CrossRef] [PubMed]

215. Franz, M.J.; VanWormer, J.J.; Crain, A.L.; Boucher, J.L.; Histone, T.; Caplan, W.; Bowman, J.D.; Pronk, N.P. Weight-Loss Outcomes: A Systematic Review and Meta-Analysis of Weight-Loss Clinical Trials with a Minimum 1-Year Follow-Up. J. Am. Diet. Assoc. 2007, 107, 1755–1767. [CrossRef] [PubMed]

216. Li, G.; Xie, C.; Lu, S.; Nichols, R.G.; Tian, Y.; Li, L.; Patel, D.; Ma, Y.; Brocker, C.N.; Yan, T.; et al. Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the Gut Microbiota. Cell Metab. 2017, 26, 672–685.e4. [CrossRef]

217. Patterson, R.E.; Sears, D.D. Metabolic Effects of Intermittent Fasting. Annu. Rev. Nutr. 2017, 37, 371–393. [CrossRef]

218. Flanagan, A.; Bechtold, D.A.; Pot, G.K.; Johnston, J.D. Chrono-nutrition: From molecular and neuronal mechanisms to human epidemiology and timed feeding patterns. J. Neurochem. 2020, 157, 53–72. [CrossRef]

219. Lessan, N.; Ali, T. Energy Metabolism and Intermittent Fasting: The Ramadan Perspective. Nutrients 2019, 11, 1192. [CrossRef]

220. Anton, S.D.; Moehl, K.; Donahoo, W.T.; Marosi, K.; Lee, S.A.; Mainous, A.G., 3rd; Leeuwenburgh, C.; Mattson, M.P. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity 2018, 26, 254–268. [CrossRef]
247. Bodosi, B.; Gardi, J.; Hajdu, I.; Szentirmai, E.; Obal, F.; Krueger, J.M. Rhythms of ghrelin, leptin, and sleep in rats: Effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. *Am. J. Physiol.-Regul. Integr. Comp. Physiol.* 2004, 287, R1071–R1079. [CrossRef]

248. Sinha, M.K.; Ohannesian, J.P.; Heiman, M.L.; Kriauciunas, A.; Stephens, T.W.; Magson, S.; Maro, C.; Cano, J.F. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. *J. Clin. Invest.* 1996, 97, 1344–1347. [CrossRef]

249. Suriagandhi, V.; Nachiapvan, V. Protective Effects of Melatonin against Obesity-Induced by Leptin Resistance. *Behav. Brain Res.* 2022, 417, 113598. [CrossRef]

250. Kettner Nicole, M.; Mayo Sara, A.; Hua, J.; Lee, C.; Moore David, D.; Fu, L. Circadian Dysfunction Induces Leptin Resistance in Mice. *Cell Metab.* 2015, 22, 448–459. [CrossRef]

251. Shapiro, A.; Mu, W.; Roncal, C.; Cheng, K.-Y.; Johnson, R.J.; Scarpace, P.I. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. *Am. J. Physiol.-Regul. Integr. Comp. Physiol.* 2008, 295, R1370–R1375. [CrossRef]

252. Lin, S.; Thomas, T.; Storlien, L.; Huang, X. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6 mice. *Int. J. Obes.* 2000, 24, 639–646. [CrossRef]

253. Chan, J.L.; Heist, K.; DePaoli, A.M.; Veldhuis, J.D.; Mantzoros, C.S. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. *J. Clin. Invest.* 2003, 111, 1409–1421. [CrossRef] [PubMed]

254. Spezani, R.; da Silva, R.R.; Martins, F.F.; de Souza Marinho, T.; Aguilá, M.B.; Mandarim-de-Lacerda, C.A. Intermittent fasting, adipokines, insulin sensitivity, and hypothalamic neuropeptides in a dietary overflow with high-fat or high-fructose diet in mice. *J. Nutr. Biochem.* 2020, 83, 108419. [CrossRef] [PubMed]

255. Cho, Y; Hong, N.; Kim, K.-W.; Cho, S.J.; Lee, A.; Lee, Y.-H.; Lee, Y.H.; Kang, E.S.; Cha, B.S.; Lee, B.W. The Effectiveness of Intermittent Fasting to Reduce Body Mass Index and Glucose Metabolism: A Systematic Review and Meta-Analysis. *J. Clin. Med.* 2019, 8, 1645. [CrossRef] [PubMed]

256. Albosta, M.; Bakke, J. Intermittent fasting: Is there a role in the treatment of diabetes? A review of the literature and guide for primary care physicians. *Clin. Diabetes Endocrinol.* 2021, 7, 3. [CrossRef] [PubMed]

257. Kahn, B.B.; Alquier, T.; Carling, D.; Hardie, D.G. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab.* 2008, 1, 15–25. [CrossRef]

258. Minokoshi, Y.; Alquier, T.; Furukawa, N.; Kim, Y.-B.; Lee, A.; Xue, B.; Mu, J.; Foufelle, F.; Ferré, P.; Birnbaum, M.J.; et al. AMP kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* 2004, 428, 569–574. [CrossRef]

259. Scarpace, P.J.; Matheny, M.; Pollock, B.H.; Türmer, N. Leptin increases uncoupling protein expression and energy expenditure. *Am. J. Physiol.* 1997, 273 Pt 1, E226–E230. [CrossRef]

260. Biancolin, A.D.; Martchenko, A.; Mitova, E.; Gurges, P.; Michalchysyn, E.; Chalmers, J.A.; Doria, A.; Mychaleckyj, J.C.; Adriaenssens, A.E.; Reimann, F.; et al. The core clock gene, Bmal1, and its downstream target, the SNARE regulatory protein secretagogin, are necessary for circadian secretion of glucagon-like peptide-1. *Mol. Metab.* 2020, 31, 124–137. [CrossRef]

261. Hill, B.R.; De Souza, M.J.; Williams, N.I. Characterization of the diurnal rhythm of peptide YY and its association with energy balance parameters in normal-weight premenopausal women. *Am. J. Physiol.-Endocrinol. Metab.* 2011, 301, E409–E415. [CrossRef] [PubMed]

262. Weyer, M.C.; van Meer, G.; Charbonnier, L.; Crabtree, D.R.; Fu, L. Circadian Dysfunction Induces Leptin Resistance in Mice. *Cell Metab.* 2008, 15, e237922. [CrossRef] [PubMed]

263. Wever, M.C.; van Meer, G.; Crabtree, D.R.; Buosi, W.; Giannopoulou, A.; Androuotos, O.; Johnstone, A.M.; Manios, Y.; Meek, C.L.; et al. Associations between ghrelin and leptin and neural food cue reactivity in a fasted and sated state. *Neuroimage* 2021, 240, 118374. [CrossRef]

264. Cummings, D.E.; Weigle, D.S.; Frayo, R.S.; Breen, P.A.; Ma, M.K.; Dellingere, E.P.; Purnell, J.Q. Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery. *N. Engl. J. Med.* 2002, 346, 1623–1630. [CrossRef] [PubMed]

265. Sumithran, P.; Prendergast, L.A.; Delbridge, E.; Purcell, K.; Shulkes, A.; Kriketos, A.; Proietto, J. Long-Term Persistence of Hormonal Adaptations to Weight Loss. *N. Engl. J. Med.* 2011, 365, 1597–1604. [CrossRef] [PubMed]

266. Lean, M.E.J.; Maltova, D. Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence? *Int. J. Obes.* 2015, 40, 622–632. [CrossRef] [PubMed]

267. Al-Rawi, N.; Madkour, M.; Jahrami, H.; Salahat, D.; Alhasan, F.; BaHamman, A.; Faris, M.A.-I. Effect of diurnal intermittent fasting during Ramadan on ghrelin, leptin, melatonin, and cortisol levels among overweight and obese subjects: A prospective observational study. *PloS ONE 2020*, 15, e0237922. [CrossRef] [PubMed]

268. Alzoghbi, M.A.; Pandi-Perumal, S.R.; Sharif, M.M.; BaHamman, A.S. Diurnal Intermittent Fasting during Ramadan: The Effects on Leptin and Ghrelin Levels. *PloS ONE 2014*, 9, e92214. [CrossRef]

269. Omsade, A.; Buxton, O.M.; Rusak, B. Impact of acute sleep restriction on cortisol and leptin levels in young women. *Physiol. Behav.* 2010, 99, 651–656. [CrossRef]

270. Nedeltcheva, A.V.; Kilkus, J.M.; Imperial, J.; Schoeller, D.A.; Penev, P.D. Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity. *Ann. Intern. Med.* 2010, 153, 435. [CrossRef]

271. Hayes, A.L.; Xu, F.; Babineau, D.; Patel, S.R. Sleep Duration and Circulating Adipokine Levels. *Sleep 2011*, 34, 147–152. [CrossRef]

272. Ali, R.; Tarig, S.; Kareem, O.; Fayaz, F.; Aziz, T.; Pottoo, F.H.; Siddiqui, N. Nutraceuticals for Sleep Disorders. *Comb. Chem. High Throughput Screen.* 2021, 24, 1583–1592. [CrossRef]

273. Godes, J.; Ferri, R.; Castellano, S.; Angelino, D.; Mena, P.; Del Rio, D.; Caraci, F.; Galvano, F.; Grosso, G. Specific Dietary (Poly)phenols Are Associated with Sleep Quality in a Cohort of Italian Adults. *Nutrients* 2020, 12, 1226. [CrossRef]

274. Canto, C.; Auverx, J. Calorie Restriction: Is AMPK a Key Sensor and Effector? *Physiology 2011*, 26, 214–224. [CrossRef] [PubMed]
274. Meng, Q.-J.; Logunova, L.; Maywood, E.S.; Gallego, M.; Lebiecki, J.; Brown, T.M.; Sládek, M.; Semikhodskii, A.S.; Glossop, N.R.; Piggins, H.D.; et al. Setting Clock Speed in Mammals: The CK1ε tau Mutation in Mice Accelerates Circadian Pacemakers by Selectively Destabilizing PERIOD Proteins. Neuron 2008, 58, 78–88. [CrossRef] [PubMed]

275. Lamia, K.A.; Sachdeva, U.M.; DiTacchio, L.; Williams, E.C.; Alvarez, J.G.; Egan, D.F.; Vasquez, D.S.; Juguilon, H.; Panda, S.; Shaw, R.J.; et al. AMPK Regulates the Circadian Clock by Cryptochrome Phosphorylation and Degradation. Science 2009, 326, 437–440. [CrossRef] [PubMed]

276. Sherman, H.; Genzer, Y.; Cohen, R.; Chapnik, N.; Madar, Z.; Froy, O. Timed high-fat diet resets circadian metabolism and prevents obesity. FASEB J. 2012, 26, 3493–3502. [CrossRef] [PubMed]

277. Poljsak, B. NAMPT-Mediated NAD Biosynthesis as the Internal Timing Mechanism: In NAD+ World, Time Is Running in Its Own Way. Rejuvenation Res. 2018, 21, 210–224. [CrossRef] [PubMed]

278. Yamaguchi, S.; Yoshino, J. Adipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapy. BioEssays 2017, 39, 1600227. [CrossRef]

279. Levine, D.C.; Ramsey, K.M.; Bass, J. Circadian NAD(P)(H) cycles in cell metabolism. Semin. Cell Dev. Biol. 2022, 126, 15–26. [CrossRef]

280. Ramsey, K.M.; Yoshino, J.; Brace, C.S.; Abrassart, D.; Kobayashi, Y.; Marcheva, B.; Hong, H.-K.; Chong, J.L.; Buhr, E.D.; Lee, C.; et al. Circadian Clock Feedback Cycle through NAMPT-Mediated NAD+ Biosynthesis. Science 2009, 324, 651–654. [CrossRef]

281. Fulco, M.; Cen, Y.; Zhao, P.; Hoffman, E.P.; McBurney, M.W.; Sauve, A.A.; Sartorelli, A. Glucose Restriction Inhibits Skeletal Myoblast Differentiation by Activating SIRT1 through AMPK-Mediated Regulation of Namp. Dev. Cell 2008, 14, 661–673. [CrossRef]

282. Yoshino, J.; Mills Kathryn, F.; Yoon, M.; Imai, S. Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice. Cell Metab. 2011, 14, 528–536. [CrossRef]

283. Canto, C.; Jiang, L.Q.; Deshmukh, A.S.; Matakai, C.; Coste, A.; Lagouge, M.; Zierath, J.R.; Auwerx, J. Interdependence of AMPK and SIRT1 for Metabolic Adaptation to Fasting and Exercise in Skeletal Muscle. Cell Metab. 2010, 11, 212–219. [CrossRef] [PubMed]

284. Nakahata, Y.; Sahar, S.; Astarita, G.; Kaluzova, M.; Sassone-Corsi, P. Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1. Science 2009, 324, 654–657. [CrossRef] [PubMed]

285. Poljsak, B.; Kovač, V.; Milisavl, I. Healthy Lifestyle Recommendations: Do the Beneficial Effects Originate from NAD+ Amount at the Cellular Level? Myers N, editor. Oxidative Med. Cell. Longev. 2020, 2020, 8819627. [CrossRef]

286. Houtkooper, R.H.; Pirinen, E.; Auwerx, J. Sirtuins and calorie restriction. Nat. Rev. Mol. Cell Biol. 2012, 13, 225–238. [CrossRef] [PubMed]

287. Bordone, L.; Guarente, L. SIRT1 is an internal control of circadian clock regulation: Understanding longevity. Nat. Rev. Mol. Cell Biol. 2013, 14, 296–305. [CrossRef] [PubMed]

288. Guarente, L. Sirtuins and calorie restriction. Nat. Rev. Mol. Cell Biol. 2012, 13, 207. [CrossRef]

289. Guarente, L. Calorie restriction and sirtuins revisited. Genes Dev. 2013, 27, 2072–2085. [CrossRef]

290. Yu, W.; Qin, J.; Chen, C.; Fu, Y.; Wang, W. Moderate calorie restriction attenuates age-associated alterations and improves cardiac function by increasing SIRT1 and SIRT3 expression. Mol. Med. Rep. 2018, 18, 4087–4094. [CrossRef]

291. Cantó, C. Dietary restriction and Sirtuin 1 in metabolic health: Connections and divergences. Proc. Nutr. Soc. 2015, 75, 30–37. [CrossRef]

292. Watsroa, M.; Szuikiewicz, D. Sirtuins at the Service of Healthy Longevity. Front. Physiol. 2021, 12, 724506. [CrossRef]

293. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F.W.; Schibler, U. SIRT1 Regulates Circadian Clock Gene Expression through PER2 Deacetylation. Cell 2008, 134, 317–328. [CrossRef] [PubMed]

294. Nakahata, Y.; Kaluzova, M.; Grimaldi, B.; Sahar, S.; Hirayama, J.; Chen, D.; Guarente, L.P.; Sassone-Corsi, P. The NAD+-Dependent Deacetylase SIRT1 Modulates CLOCK-Mediated Chromatin Remodeling and Circadian Control. Cell 2008, 134, 329–340. [CrossRef] [PubMed]

295. Chang, H.-C.; Guarente, L. SIRT1 Mediates Central Circadian Control in the SCN by a Mechanism that Decays with Aging. Cell 2013, 153, 1448–1460. [CrossRef] [PubMed]

296. Wang, R.-H.; Zhao, T.; Cui, K.; Hu, G.; Chen, Q.; Chen, W.; Wang, X.-W.; Soto-Gutierrez, A.; Zhao, K.; Deng, C.-X. Negative reciprocal regulation between Sirt1 and Per2 modulates the circadian clock and aging. Sci. Rep. 2016, 6, 28633. [CrossRef]

297. Terada, S.; Goto, M.; Kato, M.; Kawanaka, K.; Shimokawa, T.; Tabata, I. Effects of Low-intensity Prolonged Exercise on PGC-1α mRNA Expression in Rat Epitrochlearis Muscle. Biochem. Biophys. Res. Commun. 2002, 296, 350–354. [CrossRef]

298. Cantó, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.; Auwerx, J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458, 1056–1060. [CrossRef]

299. Jäger, S.; Handschin, C.; St-Pierre, J.; Spiegelman, B.M. AMP-activated Protein Kinase (AMPK) Action in Skeletal Muscle via Direct Phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA 2007, 104, 12017–12022. [CrossRef]

300. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280, 17187–17195. [CrossRef]

301. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280, 17187–17195. [CrossRef] [PubMed]

302. Gertz, M.; Nguyen, G.T.T.; Fischer, F.; Suenkel, B.; Schlicker, C.; Fränzel, B.; Tomaschewski, J.; Aladini, F.; Becker, C.; Wolters, D.; et al. A Molecular Mechanism for Direct Sirtuin Activation by Resveratrol. PLoS ONE 2012, 7, e49761. [CrossRef] [PubMed]

303. Iside, C.; Scafuro, M.; Nebbioso, A.; Altucci, L. SIRT1 Activation by Natural Phytochemicals: An Overview. Front. Pharmacol. 2020, 11, 1225. [CrossRef] [PubMed]
303. Akan, O.D.; Qin, D.; Guo, T.; Lin, Q.; Luo, F. Sirtfoods: New Concept Foods, Functions, and Mechanisms. *Foods* **2022**, *11*, 2955. [CrossRef] [PubMed]

304. Pallauñ, K.; Giller, K.; Huebbe, P.; Rimbach, G. Nutrition and Healthy Ageing: Calorie Restriction or Polyphenol-Rich “Mediterranean Diet”? *Oxidative Med. Cell. Longev.* **2013**, *2013*, 707421. [CrossRef]

305. Chung, S.; Yao, H.; Caiyo, S.; Hwang, J.; Arunachalam, G.; Rahman, I. Regulation of SIRT1 in cellular functions: Role of polyphenols. *Arch. Biochem. Biophys.* **2010**, *501*, 79–90. [CrossRef] [PubMed]

306. Sarubbo, F.; Esteban, S.; Miralles, A.; Moranta, D. Effects of Resveratrol and other Polyphenols on Sirt1: Relevance to Brain Function During Aging. *Curr. Neuropharmacol.* **2018**, *16*, 126–136. [CrossRef] [PubMed]

307. Ye, Y.; Xu, H.; Xie, Z.; Wang, L.; Sun, Y.; Yang, H.; Hu, D.; Mao, Y. Time-Restricted Feeding Reduces the Detrimental Effects of a High-Fat Diet, Possibly by Modulating the Circadian Rhythm of Hepatic Lipid Metabolism and Gut Microbiota. *Front. Nutr.* **2020**, *7*, 596285. [CrossRef]

308. Cantó, C.; Menzies Keir, J.; Auwerx, J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. *Cell Metab.* **2015**, *22*, 31–53. [CrossRef]

309. Yang, Y.; Sáuve, A. A. NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy. *Biochim. Biophys. Acta* **2016**, *1864*, 1787–1800. [CrossRef]

310. Bai, P.; Cantó, C.; Oudart, H.; Brunyánszki, A.; Cen, Y.; Thomas, C.; Yamamoto, H.; Huber, A.; Kiss, B.; Houtkooper, R.H.; et al. PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation. *Cell Metab.* **2011**, *13*, 461–468. [CrossRef] [PubMed]

311. Szántó, M.; Bai, P. The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism. *Genes Dec.* **2020**, *34*, 321–340. [CrossRef] [PubMed]

312. Vernochet, C.; Peres, S.B.; Davis, K.E.; McDonald, M.E.; Qiang, L.; Wang, H.; Scherer, P.E.; Farmer, S.R. C/EBPβ and Mitochondrial Biogenesis: A Reevaluation. *Proc. Nutr. Soc.* **2019**, *78*, 426–437. [CrossRef] [PubMed]

313. Rodgers, J.T.; Puigserver, P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 12861–12866. [CrossRef] [PubMed]

314. Gerhart-Hines, Z.; Rodgers, J.T.; Bare, O.; Lerin, C.; Kim, S.-H.; Mostoslavsky, R.; Alt, F.W.; Wu, Z.; Puigserver, P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. *EMBO J.* **2007**, *26*, 1913–1923. [CrossRef] [PubMed]

315. Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Puigserver, P.; Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. *Nature* **2005**, *434*, 113–118. [CrossRef]

316. Popov, L. Mitochondrial biogenesis: An update. *Cell. Mol. Med.* **2020**, *24*, 4892–4899. [CrossRef]

317. Higashida, K.; Kim, S.H.; Jung, S.R.; Asaka, M.; Holloszy, J.O.; Han, D.-H. Effects of Resveratrol and SIRT1 on PGC-1α Activity and Mitochondrial Biogenesis: A Reevaluation. *PLoS Biol.* **2013**, *11*, e1001603. [CrossRef] [PubMed]

318. Cantó, C.; Auwerx, J. PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. *Curr. Opin. Lipidol.* **2009**, *20*, 98–105. [CrossRef]

319. Gurd, B.J. Deacetylation of PGC-1α by SIRT1: Importance for skeletal muscle function and exercise-induced mitochondrial biogenesis. *Appl. Physiol. Nutr. Metab.* **2011**, *36*, 589–597. [CrossRef]

320. Tang, B. Sirt1 and the Mitochondria. *Mol. Cells* **2016**, *39*, 87–95. [CrossRef] [PubMed]

321. Sanchis-Gomar, F.; Garcia-Gimenez, J.; Gomez-Cabreraz, M.; Pallardo, F. Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches. *Curr. Pharm. Des.* **2016**, *22*, 361–373. [CrossRef] [PubMed]

322. Oryang, I.G.; Lu, J.; Rodova, M.; Lezi, E.; Crafter, A.B.; Sverdlov, R.H. Regulation of neuron mitochondrial biogenesis and relevance to brain health. *Biochim. Biophys. Acta (BBAJ-Mol. Basis Dis)* **2010**, *1802*, 228–234. [CrossRef] [PubMed]

323. Whitaker, R.M.; Corum, D.; Beeson, C.C.; Schnellmann, R.G. Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases. *Annu. Rev. Pharmacol. Toxicol.* **2016**, *56*, 229–249. [CrossRef] [PubMed]

324. Goede, P.; Wüst, R.C.I.; Schomakers, B.V.; Denis, S.; Vaz, F.M.; Pras-Raves, M.L.; Weeghel, M.; Yi, C.; Kalsbeek, A.; Houtkooper, R.H. Time-restricted feeding during the inactive phase abolishes the daily rhythm in mitochondrial respiration in rat skeletal muscle. *FASEB J.* **2022**, *36*, e22133. [CrossRef] [PubMed]

325. Davinelli, S.; De Stefani, D.; De Vivo, I.; Scapagnini, G. Polyphenols as Caloric Restriction Mimetics Regulating Mitochondrial Biogenesis and Mitophagy. *Trends Endocrinol. Metab.* **2020**, *31*, 536–550. [CrossRef]
329. Chodari, L.; Aytemir, M.D.; Vahedi, P.; Alipour, M.; Vahed, S.Z.; Khatibi, S.M.H.; Ahmadian, E.; Ardalan, M.; Eftekhari, A. Targeting Mitochondrial Biogenesis with Polyphenol Compounds. de Oliveira FL, editor. Oxidative Med. Cell. Longev. 2021, 2021, 4946711. [CrossRef]

330. Wang, Z.; Yang, Z.; Liu, J.; Hao, Y.; Sun, B.; Wang, J. Potential Health Benefits of Whole Grains: Modulation of Mitochondrial Biogenesis and Energy Metabolism. J. Agric. Food Chem. 2021, 69, 14065–14074. [CrossRef]

331. Cypess, A.M.; Kahn, C.R. The role and importance of brown adipose tissue in energy homeostasis. Curr. Opin. Pediatr. 2010, 22, 478–484. [CrossRef]

332. Lo, K.; Sun, L. Turning WAT into BAT: A review on regulators controlling the browning of white adipocytes. Int. J. Mol. Sci. 2021, 13, 335. [CrossRef] [PubMed]

333. Wang, Z.; Yang, Z.; Liu, J.; Hao, Y.; Sun, B.; Wang, J. Potential Health Benefits of Whole Grains: Modulation of Mitochondrial Biogenesis and Energy Metabolism. J. Agric. Food Chem. 2021, 69, 14065–14074. [CrossRef]

334. Heyde, I.; Begemann, K.; Oster, H. Contributions of white and brown adipose tissues to the circadian regulation of energy metabolism. Endocrinology 2021, 162, bqab009. [CrossRef] [PubMed]

335. Seale, P.; Kajimura, S.; Yang, W.; Chin, S.; Rohas, L.M.; Uldry, M.; Tavernier, G.; Langin, D.; Spiegelman, B.M. Transcriptional Control of Brown Fat Determination by PRDM16. Cell Metab. 2007, 6, 38–54. [CrossRef]

336. Heyde, I.; Begemann, K.; Oster, H. Contributions of white and brown adipose tissues to the circadian regulation of energy metabolism. Endocrinology 2021, 162, bqab009. [CrossRef] [PubMed]

337. Seale, P.; Kajimura, S.; Yang, W.; Chin, S.; Rohas, L.M.; Uldry, M.; Tavernier, G.; Langin, D.; Spiegelman, B.M. Transcriptional Control of Brown Fat Determination by PRDM16. Cell Metab. 2007, 6, 38–54. [CrossRef]

338. Ohno, H.; Shinoda, K.; Spiegelman Bruce, M.; Kajimura, S. PPARα agonists Induce a White-to-Brown Fat Conversion through Stabilization of PRDM16 Protein. Cell Metab. 2012, 15, 395–404. [CrossRef]

339. Mollner, C.; Auclair, M.; Le Cam, G.; Garcia, M.; Antoine, B. The nuclear retinoid-related orphan receptor RORα controls circadian thermogenic programming in white fat depots. Physiol. Rep. 2018, 6, e13678. [CrossRef]

340. Weger, M.; Diotel, N.; Dorsemans, A.-C.; Dickmeis, T.; Weger, B.D. Stem cells and the circadian clock. Curr. Opin. Cell Biol. 2017, 43, 111–123. [CrossRef]

341. Nam, D.; Chatterjee, S.; Yin, H.; Liu, R.; Lee, J.; Yechoor, V.K.; Ma, K. Novel Function of Rev-erba in Promoting Brown Adipogenesis. Scit. Rep. 2015, 5, 11239. [CrossRef]

342. Lettieri Barbato, D.; Baldelli, S.; Pagliuca, B.; Aquilano, K.; Ciriolo, M.R. Caloric Restriction and the Nutrient-Sensing PGC-1α in Promoting Brown Adipogenesis. Sci. Rep. 2021, 11, 8701. [CrossRef]

343. Li, S.; Yu, Q.; Wang, G.-X.; Lin, J.D. The Biological Clock is Regulated by Adrenergic Signaling in Brown Fat but is Dispensable for Cold-Induced Thermogenesis. PLoS ONE 2013, 8, e70109. [CrossRef]

344. Heyde, I.; Begemann, K.; Oster, H. Contributions of white and brown adipose tissues to the circadian regulation of energy metabolism. Endocrinology 2021, 162, bqab009. [CrossRef] [PubMed]

345. Seale, P.; Kajimura, S.; Yang, W.; Chin, S.; Rohas, L.M.; Uldry, M.; Tavernier, G.; Langin, D.; Spiegelman, B.M. Transcriptional Control of Brown Fat Determination by PRDM16. Cell Metab. 2007, 6, 38–54. [CrossRef]

346. Lettieri Barbato, D.; Baldelli, S.; Pagliuca, B.; Aquilano, K.; Ciriolo, M.R. Caloric Restrictio...n-Sensing PGC-1α and exercise in the control of body weight. Int. J. Obes. 2012, 395–404. [CrossRef]

347. Miller, K.N.; Clark, J.P.; Martin, S.A.; Howell, P.R.; Burhans, M.S.; Haws, S.A.; Johnson, N.B.; Rhoads, T.W.; Pavelec, D.M.; Elce, C.; et al. PGC-1α integrates a metabolism and growth network linked to caloric restriction. Aging Cell 2019, 18, e12999. [CrossRef] [PubMed]

348. Kobayashi, M.; Deguchi, Y.; Nozaki, Y.; Higami, Y. Contribution of PGC-1α to Obesity- and Caloric Restriction-Related Physiological Changes in White Adipose Tissue. Int. J. Mol. Sci. 2021, 22, 6025. [CrossRef] [PubMed]

349. Lira, V.A.; Benton, C.R.; Yan, Z.; Bonen, A. PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. Am. J. Physiol.-Endocrinol. Metab. 2010, 299, E145–E161. [CrossRef] [PubMed]

350. Miller, K.N.; Clark, J.P.; Martin, S.A.; Howell, P.R.; Burhans, M.S.; Haws, S.A.; Johnson, N.B.; Rhoads, T.W.; Pavelec, D.M.; Elce, C.; et al. PGC-1α integrates a metabolism and growth network linked to caloric restriction. Aging Cell 2019, 18, e12999. [CrossRef] [PubMed]

351. Lira, V.A.; Benton, C.R.; Yan, Z.; Bonen, A. PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. Am. J. Physiol.-Endocrinol. Metab. 2010, 299, E145–E161. [CrossRef] [PubMed]

352. Summerratter, S.; Handschun, C. PGC-1α and exercise in the control of body weight. Int. J. Obes. 2012, 36, 1428–1435. [CrossRef] [PubMed]

353. Vidal, P.; Stanford, K.I. Exercise-Induced Adaptations to Adipose Tissue Thermogenesis. Front. Endocrinol. 2020, 11, 270. [CrossRef]

354. Vidal, P.; Stanford, K.I. Exercise-Induced Adaptations to Adipose Tissue Thermogenesis. Front. Endocrinol. 2020, 11, 270. [CrossRef]

355. Angui, S.; Chayah, M.; Bouguerra-Aouichat, S.; Agil, A. Time-Restricted Feeding Improves Body Weight Gain, Lipid Profiles, and Atherogenic Indices in Cafeteria-Diet-Fed Rats: Role of Browning of Inguinal White Adipose Tissue. Nutrients 2020, 12, 2185. [CrossRef]

356. Angui, S.; Chayah, M.; Bouguerra-Aouichat, S.; Agil, A. Time-Restricted Feeding Improves Body Weight Gain, Lipid Profiles, and Atherogenic Indices in Cafeteria-Diet-Fed Rats: Role of Browning of Inguinal White Adipose Tissue. Nutrients 2020, 12, 2185. [CrossRef]

357. Goede, P.; Hellings, T.P.; Coopmans, T.V.; Ritsema, W.I.G.R.; Kalsbeek, A. After-Effects of Time-Restricted Feeding on Whole-Body Metabolism and Gene Expression in Four Different Peripheral Tissues. Obesity 2020, 28, S68–S80. [CrossRef]

358. Persinger, A.; Butawan, M.; Faietti, M.; Pryke, A.; Rose, K.; van der Merwe, M.; Bloomer, R.; Puppa, M. Effects of Feeding Time on Markers of Muscle Metabolic Flexibility Following Acute Aerobic Exercise in Trained Mice Undergoing Time Restricted Feeding. Nutrients 2021, 13, 1717. [CrossRef]

359. Vieira, R.F.L.; Muñoz, V.R.; Junqueira, R.L.; Oliveira, F.; Gaspar, R.C.; Nakandakari, S.C.B.R.; Costa, S.D.O.; Torsoni, M.A.; da Silva, A.S.; Cintra, D.E.; et al. Time-restricted feeding combined with aerobic exercise training can prevent weight gain and improve metabolic disorders in mice fed a high-fat diet. J. Physiol. 2021, 600, 797–813. [CrossRef]

360. Rodrigues, L.G.F.; de Araujo, L.D.; Roa, S.L.R.; Bueno, A.C.; Uchoa, E.T.; Antunes-Rodrigues, J.; Moreira, A.C.; Elias, L.L.K.; de Castro, M.; Martins, C.S. Restricted feeding modulates peripheral clocks and nutrient sensing pathways in rats. Arch. Endocrinol. Metab. 2021, 65, 549–561. [CrossRef] [PubMed]

361. Rodrigues, L.G.F.; de Araujo, L.D.; Roa, S.L.R.; Bueno, A.C.; Uchoa, E.T.; Antunes-Rodrigues, J.; Moreira, A.C.; Elias, L.L.K.; de Castro, M.; Martins, C.S. Restricted feeding modulates peripheral clocks and nutrient sensing pathways in rats. Arch. Endocrinol. Metab. 2021, 65, 549–561. [CrossRef] [PubMed]

362. de Oliveira FL, editor. Oxidative Med. Cell. Longev. 2021, 2021, 4946711. [CrossRef]
355. Davinelli, S.; Sapere, N.; Visentin, M.; Zella, D.; Scapagnini, G. Enhancement of mitochondrial biogenesis with polyphenols: Combined effects of resveratrol and equol in human endothelial cells. *Inn. Ageing* 2013, 10, 28. [CrossRef] [PubMed]

356. Voigt, R.M.; Forsyth, C.B.; Green, S.J.; Mutlu, E.; Engen, P.; Vitaterna, M.H.; Turek, F.W.; Keshavarzian, A. Circadian Disorganization Alters Intestinal Microbiota. *PLoS ONE* 2014, 9, e97500. [CrossRef]

357. Voigt, R.M.; Summa, K.C.; Forsyth, C.B.; Green, S.J.; Engen, P.; Naqib, A.; Vitaterna, M.H.; Turek, F.W.; Keshavarzian, A. The Circadian Clock Mutation Promotes Intestinal Dysbiosis. *Alcohol. Clin. Exp. Res.* 2016, 40, 335–347. [CrossRef]

358. Thaiss Christoph, A.; Zezei, D.; Levy, M.; Zilberman-Schapira, G.; Suez, J.; Tengeler Anouk, C.; Abramson, L.; Katz, M.N.; Korem, T.; Zmora, N.; et al. Transkingdom Control of Microbiota Diurnal Oscillations Promotes Metabolic Homeostasis. *Cell* 2014, 159, 514–529. [CrossRef]

359. Zarrinpar, A.; Chaix, A.; Yooseph, S.; Panda, S. Diet and Feeding Pattern Affect the Diurnal Dynamics of the Gut Microbiome. *Cell Metab.* 2014, 20, 1006–1017. [CrossRef]

360. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Human gut microbes associated with obesity. *Nature* 2006, 444, 1022–1023. [CrossRef]

361. Deng, Y.; Liu, W.; Wang, J.; Yu, J.; Yang, L. Intermittent Fasting Improves Lipid Metabolism Through Changes in Gut Microbiota in Diet-Induced Obese Mice. *Med. Sci. Monit.* 2020, 26, e926789-1–e926789-11. [CrossRef]

362. Patterson, R.E.; Laughlin, G.A.; LaCroix, A.Z.; Natarajan, L.; Senger, C.M.; Martinez, M.E.; Villaseñor, A.; Sears, D.D.; Marinac, C.R.; et al. Intermittent Fasting and Human Metabolic Health. *J. Acad. Nutr. Diet.* 2015, 115, 1203–1212. [CrossRef]

363. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006, 444, 1027–1031. [CrossRef] [PubMed]

364. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Affourtit, J.P.; et al. A core gut microbiome in obese and lean twins. *Nature* 2008, 457, 480–484. [CrossRef]

365. Cui, Y.; Li, S.; Yin, Y.; Li, X.; Li, X. Daytime restricted feeding promotes circadian desynchrony and metabolic disruption with changes in bile acids profiles and gut microbiota in C57BL/6 Male Mice. *J. Nutr. Biochem.* 2022, 109, 109121. [CrossRef] [PubMed]

366. Wang, X.; Qi, Y.; Zheng, H. Dietary Polyphenol, Gut Microbiota, and Health Benefits. *Antioxidants* 2022, 11, 1212. [CrossRef]

367. Molinari, R.; Merendino, N.; Costantini, L. Polyphenols as modulators of pre-established gut microbiota dysbiosis: State-of-the-art. *BioFactors* 2021, 48, 255–273. [CrossRef] [PubMed]

368. Hills, R.D.; Pontefract, B.A.; Mishcon, H.R.; Black, C.A.; Sutton, S.C.; Theberge, C.R. Gut Microbiome: Profound Implications for Diet and Disease. *Nutrients* 2019, 11, 1613. [CrossRef] [PubMed]

369. Zheng, D.; Liwinski, T.; Elinav, E. Interaction between microbiota and immunity in health and disease. *Cell Res.* 2020, 30, 492–506. [CrossRef] [PubMed]

370. De Vadder, F.; Kovatcheva-Datchary, P.; Goncalves, D.; Vina, J.; Zitoun, C.; Duchampt, A.; Bäckhed, F.; Mithieux, G. Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits. *Cell* 2014, 156, 84–96. [CrossRef] [PubMed]

371. Kumar Singh, A.; Cabral, C.; Kumar, R.; Ganguly, R.; Kumar Rana, H.; Gupta, A.; Lauro, M.R.; Carbone, C.; Reis, F.; Pandey, A.K. Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency. *Nutrients* 2019, 11, 2216. [CrossRef]

372. Leone, V.; Gibbons, S.M.; Martinez, K.; Hutchison, A.L.; Huang, E.Y.; Cham, C.M.; Pierre, J.F.; Heneghan, A.F.; Nadimpalli, A.; Hubert, N.; et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism. *Cell Host Microbe* 2015, 17, 681–689. [CrossRef]

373. Effects of alternate-day fasting, time-restricted fasting and intermittent energy restriction DSS-induced on colitis and behavioral disorders. *Redox Biol.* 2020, 32, 101535. [CrossRef] [PubMed]